Oral pharmaceutical dosage forms for gastric retention

By using swellable materials and movable arms in oral pharmaceutical dosage forms, the problem of unstable retention time in the stomach of traditional dosage forms is solved, achieving longer drug retention and more stable efficacy.

CN120076796APending Publication Date: 2025-05-30TRIASTEK INC
View PDF 23 Cites 0 Cited by

Patent Information

Application Number
CN202380073604.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-18
Filing Date
2023-10-18
Publication Date
2025-05-30

AI Technical Summary

Technical Problem

Traditional oral drug dosage forms have unstable residence time in the stomach and are greatly affected by natural forces and individual factors, resulting in inconsistent anatomical location, bioavailability and efficacy of drug delivery.

Method used

An oral pharmaceutical dosage form including a swellable material and a movable arm is designed to provide force through the expansion of the swellable material in the gastrointestinal fluid, extending the movable arm, thereby increasing the size and retention time of the dosage form.

Benefits of technology

The drug retention in the stomach for a long time is achieved, the efficacy and bioavailability of the drug are enhanced, and the dosage form is mechanically stable in the stomach and does not interfere with normal gastric function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005363210400000641
    Figure BDA0005363210400000641
  • Figure BDA0005363210400000651
    Figure BDA0005363210400000651
  • Figure BDA0005363210400000652
    Figure BDA0005363210400000652
Patent Text Reader

Abstract

In certain aspects, the present disclosure is directed to pharmaceutical dosage forms aimed at providing desired retention in an individual based on geometric differences between dosage form states before and after administration. In certain aspects, provided oral pharmaceutical dosage forms include swellable and expandable materials that upon swelling or expansion drive expansion of the overall size of the oral pharmaceutical dosage form such that the oral pharmaceutical dosage form is retained in the stomach for a desired period of time. In certain other aspects, the present disclosure is a component useful for oral pharmaceutical dosage forms taught herein. In certain other aspects, the present disclosure is directed to design methods, manufacturing methods, e.g., to three-dimensional (3D) printing, injection molding, ultrasonic welding, or any combination thereof, commercial batches, and methods of delivering drugs to individuals including administration of oral drug dosage forms described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Cross - Reference to Related Applications

[0001] This application claims priority to PCT / CN2022 / 125982, filed on October 18, 2022, and the entire disclosure of that application is incorporated herein by reference. Technical Field

[0002] In some aspects, the present disclosure is directed to pharmaceutical dosage forms designed to provide desired retention in an individual based on geometric differences between the pre - administration and post - administration states of the dosage form. In some aspects, the provided oral pharmaceutical dosage forms include swellable and expandable materials that, upon swelling or expansion, drive an increase in the overall size of the oral pharmaceutical dosage form such that the oral pharmaceutical dosage form remains in the stomach for a desired period of time. In some other aspects, the present disclosure is directed to components useful in the oral pharmaceutical dosage forms taught herein. In some other aspects, the present disclosure is directed to design methods, manufacturing methods, such as those involving three - dimensional (3D) printing, injection molding, ultrasonic welding, or any combination thereof, commercial batches, and methods of delivering a drug to an individual including administering the oral pharmaceutical dosage forms described herein. Background Art

[0003] Traditional oral pharmaceutical dosage forms, when administered to an individual, are subject to natural forces such as those of the fluids, semi - solids, and solids of the individual's gastrointestinal system, and / or forces applied by the individual such as muscle contractions, or the individual's environment such as gravity. As in the case of oral administration, such natural fluids can vary between administrations to a particular individual and between populations of individuals, depending on fluctuations relative to the time of administration, such as the timing of meals and / or beverages and the size of the meal and / or beverage contents, as well as the current gastric phase and remaining duration. These circumstances can create variability, for example, in the anatomical location of drug delivery, bioavailability, safety profile, and efficacy of a dosage form (e.g., an oral pharmaceutical dosage form) that remains in the stomach for a period of time. Summary of the Invention

[0004] In some aspects, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm can be extended beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the swellable material; and the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or an orifice operatively connected to the swellable material chamber, wherein the movable arm comprises a contact assembly configured to contact the swellable material or a feature associated with the swellable material in the vicinity of the orienting channel and the orifice; and one or more fluid inlets operatively connected to the swellable material chamber; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in a deployed form providing gastric retention, and wherein the deployed form of the post-administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0005] In some aspects, there is provided a pharmaceutical dosage form or a medical device for retention in the body, the pharmaceutical dosage form or the medical device comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm can be extended by a force provided by the swellable material, or the swellable material can rotate around the body of the pharmaceutical dosage form or the medical device; and the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; wherein the swellable material chamber operatively comprises one or more fluid inlets; an orienting channel and a swellable material orifice operatively connected to the swellable material chamber, wherein the movable arm comprises a contact assembly configured to contact the swellable material or a feature associated with the swellable material, the contact assembly being in the vicinity of the orienting channel and the orifice; and a drug, wherein the pharmaceutical dosage form or the medical device is configured to have a pre-administration state in a compact form and a post-administration state in a deployed form providing retention in the body, and wherein the deployed form of the post-administration state of the pharmaceutical dosage form or the medical device is at least partially due to the swelling of the swellable material in the presence of body fluid.

[0006] In some embodiments, the feature associated with the swellable material comprises a plunger or a piston.

[0007] In some embodiments, the movable arm or the body comprises a pivot, and the movable arm is connected to the body by the pivot.

[0008] In some embodiments, the swellable material chamber comprises a lid and a base, and the pivot of the movable arm is connected to the lid.

[0009] In some embodiments, the post-administration state of the oral pharmaceutical dosage form occurs within 1 hour or less after the oral pharmaceutical dosage form is administered to an individual.

[0010] In some embodiments, the gastric retention time of the oral pharmaceutical dosage form is from about 8 hours to about 3 months.

[0011] In some embodiments, the swellable material swells to at least about 1.2 times its volume after exposure to gastrointestinal fluids. In some embodiments, the swellable material has a volume swelling rate of at least about 1.2 times within 30 minutes.

[0012] In some embodiments, when the swellable material swells, it at least partially conforms to the shape of the directional channels and / or orifices or a portion thereof. In some embodiments, the swellable material adopts a predetermined shape and / or size when it swells.

[0013] In some embodiments, the amount of the swellable material in the swellable material chamber is at least about 5 mg.

[0014] In some embodiments, the swellable material includes sodium alginate (SA), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methylcellulose (HPMC), polyethylene oxide (PEO), polyvinyl alcohol (PVA), microcrystalline cellulose (MCC), croscarmellose sodium (CCNa), sodium carboxymethyl cellulose (CMC-Na), polyvinylpolypyrrolidone (PVPP), sodium carboxymethyl starch (CMS-Na), polyethylene glycol (PEG), or a mixture thereof. In some specific embodiments, the swellable material further includes a salt or a mixture of salts. In some embodiments, the salt is selected from the group consisting of sodium salts, magnesium salts, and potassium salts.

[0015] In some embodiments, the swellable material has a swollen volume of about 10 mm 3 to about 50 mm 3

[0016] In some embodiments, the body includes two or more components that are configured as the body. In some embodiments, the body includes one or more bases and one or more lids. In some embodiments, the body comprises two or more materials. In some embodiments, the body of the oral pharmaceutical dosage form is a unitary structure.

[0017] In some embodiments, the body presents the outer boundary of the oral pharmaceutical dosage form in the pre-administration state.

[0018] In some embodiments, the maximum cross-sectional dimension of the oral pharmaceutical dosage form in the pre-administration state is 24 mm or less. In some embodiments, at least two perpendicular dimensions of the oral pharmaceutical dosage form in the post-administration state are 20 mm or greater.

[0019] ​In some embodiments, the swellable material chamber is configured to substantially contain the swellable material in a pre - dosing state. In some embodiments, the contact assembly of the swellable material chamber and the movable arm substantially surrounds the swellable material.

[0020] In some embodiments, the guiding channel is configured to direct the movement of the movable arm through the swellable material. In some embodiments, the guiding channel includes a channel with a curved shape. In some embodiments, the guiding channel includes a circular channel. In some embodiments, the guiding channel includes a square or rectangular channel. In some embodiments, the guiding channel includes a straight channel, an oval channel, or a capsule - shaped channel.

[0021] In some embodiments, the orifice is square or rectangular.

[0022] In some embodiments, the guiding channel further includes one or more fluid inlets. In some embodiments, at least one of the one or more fluid inlets includes a semi - permeable material. In some embodiments, at least one of the one or more fluid inlets is a semi - permeable material that fills the pores formed by the body. In some embodiments, one or more fluid inlets are semi - permeable membranes that at least partially wrap around the swellable material. In some embodiments, at least one of the one or more fluid inlets is a pore.

[0023] In some embodiments, the body further forms a stop configured to engage the movable arm in an extended position. In some embodiments, the stop includes a locking assembly configured to hold the movable arm in one or more extended positions.

[0024] In some embodiments, the movable arm or a portion thereof is configured to slide within the guiding channel. In some embodiments, the contact assembly of the movable arm is configured to slide within the guiding channel. In some embodiments, the movable arm is configured to rotate about an axis.

[0025] In some embodiments, the oral dosage form further includes one or more movable arms. In some embodiments, at least two movable arms have different movement mechanisms. In some embodiments, at least two movable arms have the same movement mechanism. In some embodiments, at least two movable arms are configured such that at least a portion of each movable arm can be extended beyond or further from the body of the oral dosage form by the force provided by the swellable material.

[0026] In some embodiments, the oral pharmaceutical dosage form further comprises a second swellable material at least partially contained within a second swellable material chamber formed by the body, wherein at least one movable arm is configured such that at least a portion of the movable arm extends beyond or further from the body of the oral pharmaceutical dosage form by the force provided by the second swellable material.

[0027] In some embodiments, the oral pharmaceutical dosage form further comprises an erodible restraint configured to inhibit the extension of the movable arm. In some embodiments, the erodible restraint is eroded within about 30 minutes after administration to an individual.

[0028] In some embodiments, the drug is located in one or more of: the movable arm and the body. In some embodiments, the drug is selected from riociguat, aceclofenac, bicalutamide, carbamazepine, carvedilol, clotrimazole, cinnarizine, danazol, dapsone, estradiol, etimicin, glibenclamide, fenofibrate, griseofulvin, ibuprofen, itraconazole, ketoconazole, mefenamic acid, naproxen, nevirapine, nifedipine, nitrofurantoin, nomegestrol acetate, phenytoin sodium salt, piroxicam, praziquantel, rifampicin, sulfamethoxazole, trimethoprim, and verapamil hydrochloride.

[0029] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral pharmaceutical dosage form by the force provided by the swellable material; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel operatively connected to the swellable material chamber, wherein the movable arm includes a contact assembly configured to contact the swellable material adjacent to the orienting channel, wherein the swellable material chamber and the contact assembly of the movable arm substantially surround the swellable material, and wherein the movable arm or a portion thereof is configured to slide within the orienting channel such that the movable arm extends out of or further from the body of the oral pharmaceutical dosage form along an axis based on the orienting channel; one or more fluid inlets operatively connected to the swellable material chamber; a stop configured to engage the movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the stop includes a locking assembly configured to hold the movable arm in one or more extended positions. In some embodiments, the locking assembly is configured to hold the movable arm in a single position. In some embodiments, the locking assembly is configured to hold the movable arm in a plurality of advanced positions.

[0030] In other aspects, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended beyond or further from the body of the oral pharmaceutical dosage form by the force provided by the swellable material, wherein the first movable arm and the second movable arm extend in generally opposite directions along an axis based on a directional channel; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a first directional channel and a second directional channel operatively connected to the swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the swellable material near the second directional channel, wherein the swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm generally surround the swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel such that the first movable arm extends along the axis beyond or further from the body of the oral pharmaceutical dosage form, wherein the second movable arm or a portion thereof is configured to slide within the second directional channel such that the second movable arm extends along the axis out of or further from the body of the oral pharmaceutical dosage form; one or more fluid inlets operatively connected to the swellable material chamber; a first stop configured to engage the first movable arm in an extended position; a second stop configured to engage the second movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0031] In other aspects, provided herein is an oral dosage form for gastric retention, the oral dosage form comprising: a first swellable material; a first movable arm, wherein the first movable arm is configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral dosage form by a force provided by the first swellable material, and wherein the first movable arm is configured to rotate about a first axis; a second swellable material; a second movable arm, wherein the second movable arm is configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral dosage form by a force provided by the second swellable material, and wherein the second movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel operably connected to the first swellable material chamber, wherein the first directional channel comprises a curved channel, wherein the first movable arm comprises a first contact assembly configured to contact the first swellable material in proximity to the first directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm substantially surround the first swellable material, wherein the first movable arm or a portion thereof is configured to rotate about the first axis by the first contact assembly sliding in the first directional channel such that the first movable arm extends out or further from the body of the oral dosage form, one or more fluid inlets operably connected to the first swellable material chamber; a second swellable material chamber configured to contain at least a portion of the second swellable material; a second directional channel operably connected to the second swellable material chamber, wherein the second directional channel comprises a channel in a curved shape, wherein the second movable arm comprises a second contact assembly configured to contact the second swellable material when in proximity to the second directional channel, wherein the second swellable material chamber and the second contact assembly of the second movable arm substantially surround the second swellable material, wherein the second movable arm or a portion thereof is configured to rotate about the second axis by the second contact assembly sliding in the second directional channel such that the second movable arm extends out or further from the body of the oral dosage form, one or more fluid inlets operably connected to the second swellable material chamber; a drug, wherein the oral dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0032] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a first swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can extend beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the first swellable material, wherein the first movable arm and the second movable arm extend in generally opposite directions along an axis based on a directional channel; a second swellable material; a third movable arm, wherein the third movable arm is configured such that at least a portion of the third movable arm can extend beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the second swellable material, and wherein the third movable arm is configured to rotate about a first axis; a third swellable material; a fourth movable arm, wherein the fourth movable arm is configured such that at least a portion of the fourth movable arm can extend beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the third swellable material, and wherein the fourth movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel and a second directional channel operably connected to the first swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the first swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the first swellable material near the second directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm generally surround the first swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel such that the first movable arm extends along an axis beyond or further from the body of the oral pharmaceutical dosage form, wherein the second movable arm or a portion thereof is configured to slide within the second directional channel such that the second movable arm extends along an axis out of or further from the body of the oral pharmaceutical dosage form; one or more fluid inlets operably connected to the first swellable material chamber; a first stop configured to engage the first movable arm in an extended position; a second stop configured to engage the second movable arm in an extended position; a second swellable material chamber configured to contain at least a portion of the second swellable material;A third directional channel operably connected to the second swellable material chamber, wherein the third directional channel includes a curved channel, wherein the third movable arm includes a contact assembly configured to contact the second swellable material near the third directional channel, wherein the second swellable material chamber and the contact assembly of the third movable arm substantially surround the second swellable material, wherein the third movable arm or a portion thereof is configured to rotate about a first axis by sliding on the third directional channel through the contact assembly such that the third movable arm extends into or further out of the body of the oral dosage form, one or more fluid inlets operably connected to the third swellable material chamber; a third swellable material chamber configured to contain at least a portion of the third swellable material; a fourth directional channel operably connected to the third swellable material chamber, wherein the fourth directional channel includes a channel having a curved shape, wherein the fourth movable arm includes a contact assembly configured to contact the third swellable material near the fourth directional channel, wherein the third swellable material chamber and the contact assembly of the fourth movable arm substantially surround the third swellable material, wherein the fourth movable arm or a portion thereof is configured to rotate about a second axis by sliding on the fourth directional channel through the contact assembly such that the fourth movable arm extends into or further out of the body of the oral dosage form, one or more fluid inlets operably connected to the third swellable material chamber; and a drug, wherein the oral dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form that provides gastric retention, and wherein the expanded form of the post - dosing state of the oral dosage form is at least partially due to the swelling of the first swellable material, the second swellable material, and the third swellable material in the presence of gastrointestinal fluid.;

[0033] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm is extendable beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the swellable material, wherein the first movable arm and the second movable arm are configured to rotate in opposite directions about a shared axis; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a first guiding channel and a second guiding channel operatively connected to the swellable material chamber, wherein the first guiding channel and the second guiding channel are curved and configured about the shared axis, wherein the first movable arm includes a first contact assembly configured to contact the swellable material adjacent to the first guiding channel, wherein the first contact assembly is rudder-shaped and configured to travel in the first guiding channel such that the first movable arm rotates relative to the shared axis beyond or further from the body of the oral pharmaceutical dosage form, wherein the second movable arm includes a second contact assembly configured to contact the swellable material adjacent to the second guiding channel, wherein the second contact assembly is rudder-shaped and configured to travel in the second guiding channel such that the second movable arm rotates relative to the shared axis beyond or further from the body of the oral pharmaceutical dosage form, one or more fluid inlets operatively connected to the swellable material chamber; a stopper configured to engage the first movable arm and the second movable arm in an extended position; a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form providing gastric retention, and wherein the expanded form of the post-administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the stopper is configured to engage the first contact assembly of the first movable arm and the second contact assembly of the second movable arm in the extended position.

[0034] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates along an independent axis in a direction towards a vertical position plane by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a directional channel and / or an orifice operably connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material adjacent to the directional channel and / or the orifice, and wherein the swellable material chamber, the contact assemblies of the movable arms, and a lid substantially surround the swellable material; one or more fluid inlets operably connected to the swellable material chamber; a lid; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage with the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post-administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0035] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates along an independent axis in a direction towards a vertical position plane by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a directional channel and / or an orifice operably connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material adjacent to the directional channel and / or the orifice, and wherein the swellable material chamber and the contact assemblies of the movable arms substantially surround the swellable material; one or more fluid inlets operably connected to the swellable material chamber; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage with the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post-administration state of the oral pharmaceutical dosage form is due to at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the oral pharmaceutical dosage form further comprises an erodible restraint configured to inhibit the extension of the movable arms.

[0036] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material, wherein the swellable material is at least partially encapsulated by a semipermeable membrane; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction towards a plane of vertical position along an independent axis by a force provided by the swellable material; and a body comprising: a first connection point of the first arm, a second connection point of the second arm, a third connection point of the third arm, and a fourth connection point of the fourth arm, wherein each connection point is configured to provide an independent axis for the rotation of the first arm, the second arm, the third arm, and the fourth arm, wherein each movable arm includes a contact assembly configured to contact the swellable material or the semipermeable material, and a first stop, a second stop, a third stop, and a fourth stop, the stops being configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm, respectively, in an extended position, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the body does not include a swellable material chamber. In some embodiments, the swellable material is positioned on the body such that the swelling of the swellable material drives the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm to an extended position.

[0037] In other aspects, provided herein is a swelling structure for an oral pharmaceutical dosage form, the swelling structure comprising: a swellable material; a housing comprising: an outer shell comprising at least two layers, wherein at least two layers have successively smaller outer dimensions, wherein at least two layers are configured to have a pre - administration state in a compact form, wherein at least two of the at least two layers slide along an axis, wherein at least two layers extend along an axis and are configured to have a post - administration state in an extended form, wherein the post - administration state in the extended form provides gastric retention, and one or more fluid inlets operably connected to a swellable material chamber; wherein the swelling of the swelling structure is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, at least two layers of the outer shell are coaxial. In some embodiments, at least two layers of the outer shell are concentric.

[0038] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction along a perpendicular plane of position along an independent axis by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or an orifice operably connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material proximate to the orienting channel and / or the orifice, and wherein the swellable material chamber, the contact assemblies of the movable arms, and a lid substantially surround the swellable material; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage with the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-dose state in a compact form and a post-dose state in an expanded form providing gastric retention, and wherein the expanded form of the post-dose state of the oral pharmaceutical dosage form is at least in part due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0039] All references cited herein, including patent applications and publications, are hereby incorporated by reference in their entirety.

[0040] Those skilled in the art will also appreciate that changes may be made to the form and details of the implementations described herein without departing from the scope of the disclosure. Additionally, although various advantages, aspects, and objects have been described with reference to various implementations, the scope of the disclosure should not be limited by reference to these advantages, aspects, and objects. Brief Description of the Drawings

[0041] Figures 1A - 1D An example diagram of a pharmaceutical dosage form 100 including a swellable material 102 and movable arms 108 is shown, including a component view and a schematic view ( Figure 1C and 1D ).

[0042] Figures 2A - 2D An example diagram of a pharmaceutical dosage form 200 including a swellable material 202 and movable arms 208 is shown, including a component view and a schematic view ( Figure 2C and 2D ). Figure 2E and Figure 2F A schematic view of an example pharmaceutical dosage form 250 is shown, and the component view and the schematic view are provided in Figure 2G .

[0043] Figure 3A and Figure 3BA figure showing an example drug dosage form 300 including a swellable material 302 and a movable arm 308. For the component view and schematic diagram, see Figure 3C .

[0044] Figures 4A - 4D An example figure showing a drug dosage form 400 including a swellable material 402 and two of the movable arms 408, 418, including its component view and schematic diagram ( Figure 4C and 4D ).

[0045] Figures 5A - 5F A figure showing an example drug dosage form 500 including two movable arms 508, 520, each arm having a swellable material and a swellable material chamber respectively, including its component view and schematic diagram ( Figure 5E and 5F ).

[0046] Figures 6A - 6H A schematic diagram showing an example drug dosage form 600 including four movable arms 614, 616, 630, 632, including its component view and schematic diagram ( Figures 6E - 6H ).

[0047] Figures 7A - 7I A figure showing an example drug dosage form 700 including two movable arms 704, 706 rotating on an axis 730, including its component view and schematic diagram ( Figures 7G - 7I ).

[0048] Figures 8A - 8I A figure showing an example drug dosage form 800 including four movable arms 814, 816, 818, 820, each arm rotating along an axis, such as 824, including its component view and schematic diagram ( Figures 8E - 8I ).

[0049] Figures 9A - 9I A figure showing an example drug dosage form 900 including four movable arms 914, 916, 918, 920, each arm rotating along an axis, such as 924, including its component view and schematic diagram ( Figures 9E - 9I ).

[0050] Figures 10A - 10F A figure showing an example drug dosage form 1000 including four movable arms 1014, 1016, 1018, 1020, each arm rotating on an axis, such as 1024, including its component view ( Figure 10E and 10F ).

[0051] Figures 11A - 11EA figure showing an exemplary drug dosage form 1100, which includes four movable arms 1114, 1116, 1118, 1120, each arm rotating along an axis, such as 1124, including its component view and schematic view ( Figure 11D and 11E ).

[0052] Figures 12A - 12F A schematic view showing an exemplary swellable structure 1200, including four layers 1206, 1208, 1210, and 1212 swollen by a swellable material 1202 in the post - administration state.

[0053] Figures 13A - 13F An exemplary schematic view showing a swollen structure 1300 swollen in the post - administration state due to the swelling of a swellable material 1302, the swollen structure including four layers 1306, 1308, 1310, and 1312.

[0054] Figure 14A and 14B A figure showing an exemplary drug dosage form 1400 including a swellable material 1410, a column 1412, and four movable arms.

[0055] Figures 15A - 15D A figure showing an exemplary drug dosage form 1500 having two pairs of two movable arms rotating on a shared axis (the first movable arm 1504 and the third movable arm 1516 rotate on the first axis 1512; the second movable arm 1506 and the fourth movable arm 1518 rotate on the second axis 1514), including its component view ( Figure 15D ).

[0056] Figure 16 A picture showing an oral drug dosage form model after the swellable material has swollen.

[0057] Figure 17 A picture showing a partial model of an oral drug dosage form after the swellable material has swollen.

[0058] Figure 18 A picture showing a replica model of an oral drug dosage form and measurements of the swelling of the movable arms.

[0059] Figure 19A and Figure 19B A picture showing an X - ray image of an oral drug dosage form after administration and information on the in - vivo state of the oral drug dosage form.

[0060] Figure 20A and Figure 20B A picture showing an X - ray image of an oral drug dosage form after administration and information on the in - vivo state of the oral drug dosage form.

[0061] Figures 21A - 21CA schematic view of an exemplary pharmaceutical dosage form 2100 is shown, which dosage form includes four movable arms 2114, 2116, 2118, 2120, each arm rotating along an axis, such as 2124.

[0062] Figures 22A - 22B A figure showing an exemplary pharmaceutical dosage form 2200 is shown, which dosage form includes two movable arms 2214, 2216, each arm rotating along an axis, such as 2226.

[0063] Figure 23A and 23B Shows the in vitro state before and after drug administration.

[0064] Figure 24 Information on beagle dogs administered certain oral pharmaceutical dosage forms obtained from gastroscopy is provided.

[0065] Figure 25 The results of occult blood tests on beagle dogs administered certain oral pharmaceutical dosage forms are provided.

[0066] Figure 26 Residues of certain oral pharmaceutical dosage forms collected from the feces of beagle dogs administered certain oral pharmaceutical dosage forms are provided. Detailed Description

[0067] The oral pharmaceutical dosage forms provided herein include, in certain aspects, a swellable material that, upon swelling, drives an increase in the overall size of the oral pharmaceutical dosage form such that the oral pharmaceutical dosage form remains in the stomach for a desired period of time. The oral pharmaceutical dosage forms provided herein are at least partially based on the inventors' unique views and findings regarding the design and mechanism of oral pharmaceutical dosage forms that provide an oral pharmaceutical dosage form small enough to facilitate patient administration and that have a sufficient size increase in the stomach to inhibit the time required to pass through the pylorus (i.e., the oral pharmaceutical dosage form remains in the stomach for a longer period of time, e.g., 8 hours to 3 months). In certain aspects, the oral pharmaceutical dosage forms of the present application include one or more movable arms driven by the swelling of a swellable material, wherein the oral pharmaceutical dosage form maintains sufficient mechanical stability after the size increase to remain in the stomach for a longer period of time without disturbing normal gastric function. The pharmaceutical dosage forms of the present application can also be configured to release a drug therefrom following any desired drug release profile (e.g., an immediate release profile, a sustained release profile, a delayed-sustained release profile, a pulsatile release profile, or any combination thereof) of one or more drugs.

[0068] Accordingly, in some aspects, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm can be extended outside or further from the body of the oral pharmaceutical dosage form by a force provided by the swellable material; and the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or an orifice operatively connected to the swellable material chamber, wherein the movable arm comprises a contact assembly configured to contact the swellable material or a feature associated with the swellable material when located near the orienting channel and the orifice; and one or more fluid inlets operatively connected to the swellable material chamber; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in a deployed form providing gastric retention, and wherein the deployed form of the post-administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0069] In other aspects, there is provided herein an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm can be extended outside or further from the body of the oral pharmaceutical dosage form by a force provided by the swellable material; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel operatively connected to the swellable material chamber, wherein the movable arm comprises a contact assembly configured to contact the swellable material near the orienting channel, wherein the swellable material chamber and the contact assembly of the movable arm substantially surround the swellable material, and wherein the movable arm or a portion thereof is configured to slide within the orienting channel such that the movable arm extends out of or further away from the body of the oral pharmaceutical dosage form along an axis based on the orienting channel; one or more fluid inlets operatively connected to the swellable material chamber; a stop configured to engage the movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in a deployed form providing gastric retention, and wherein the deployed form of the post-administration state of the oral pharmaceutical dosage form is due to at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0070] In other aspects, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended outside or further from the body of the oral pharmaceutical dosage form by the force provided by the swellable material, wherein the first movable arm and the second movable arm extend in generally opposite directions along an axis based on a directional channel; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a first directional channel and a second directional channel operatively connected to the swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the swellable material near the second directional channel, wherein the swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm generally surround the swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel such that the first movable arm extends along the axis out of or further from the body of the oral pharmaceutical dosage form, wherein the second movable arm or a portion thereof is configured to slide within the second directional channel such that the second movable arm extends along the axis out of or further from the body of the oral pharmaceutical dosage form; one or more fluid inlets operatively connected to the swellable material chamber; a first stop configured to engage the first movable arm in an extended position; a second stop configured to engage the second movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0071] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a first swellable material; a first movable arm, wherein the first movable arm is configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the first swellable material, and wherein the first movable arm is configured to rotate about a first axis; a second swellable material; a second movable arm, wherein the second movable arm is configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the second swellable material, and wherein the second movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel operably connected to the first swellable material chamber, wherein the first directional channel comprises a curved channel, wherein the first movable arm comprises a first contact assembly configured to contact the first swellable material in proximity to the first directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm substantially surround the first swellable material, wherein the first movable arm or a portion thereof is configured to rotate about the first axis by the first contact assembly sliding in the first directional channel such that the first movable arm extends out or further from the body of the oral pharmaceutical dosage form, one or more fluid inlets operably connected to the first swellable material chamber; a second swellable material chamber configured to contain at least a portion of the second swellable material; a second directional channel operably connected to the second swellable material chamber, wherein the second directional channel comprises a channel in a curved shape, wherein the second movable arm comprises a second contact assembly configured to contact the second swellable material in proximity to the second directional channel, wherein the second swellable material chamber and the second contact assembly of the second movable arm substantially surround the second swellable material, wherein the second movable arm or a portion thereof is configured to rotate about the second axis by the second contact assembly sliding in the second directional channel such that the second movable arm extends out or further from the body of the oral pharmaceutical dosage form, one or more fluid inlets operably connected to the second swellable material chamber; a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in a deployed form providing gastric retention, and wherein the deployed form of the post - administration state of the oral pharmaceutical dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0072] In other aspects, provided herein is an oral dosage form for gastric retention, the oral dosage form comprising: a first swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended outside or further from the body of the oral dosage form by a force provided by the first swellable material, wherein the first movable arm and the second movable arm extend in generally opposite directions along an axis based on a directional channel; a second swellable material; a third movable arm, wherein the third movable arm is configured such that at least a portion of the third movable arm can be extended outside or further from the body of the oral dosage form by a force provided by the second swellable material, and wherein the third movable arm is configured to rotate about a first axis; a third swellable material; a fourth movable arm, wherein the fourth movable arm is configured such that at least a portion of the fourth movable arm can be extended outside or further from the body of the oral dosage form by a force provided by the third swellable material, and wherein the fourth movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel and a second directional channel operatively connected to the first swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the first swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the first swellable material near the second directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm generally surround the first swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel such that the first movable arm extends along an axis outside or further from the body of the oral dosage form, wherein the second movable arm or a portion thereof is configured to slide within the second directional channel such that the second movable arm extends along an axis out of or further from the body of the oral dosage form; one or more fluid inlets operatively connected to the first swellable material chamber; a first stop configured to engage the first movable arm in an extended position; a second stop configured to engage the second movable arm in an extended position; a second swellable material chamber configured to contain at least a portion of the second swellable material;A third directional channel operably connected to the second swellable material chamber, wherein the third directional channel includes a curved channel, wherein the third movable arm includes a contact assembly configured to contact the second swellable material near the third directional channel, wherein the second swellable material chamber and the contact assembly of the third movable arm substantially surround the second swellable material, wherein the third movable arm or a portion thereof is configured to rotate about a first axis by sliding the contact assembly along the third directional channel, such that the third movable arm extends into or further out of the body of the oral dosage form, one or more fluid inlets operably connected to the third swellable material chamber; a third swellable material chamber configured to contain at least a portion of the third swellable material; a fourth directional channel operably connected to the third swellable material chamber, wherein the fourth directional channel includes a channel having a curved shape, wherein the fourth movable arm includes a contact assembly configured to contact the third swellable material near the fourth directional channel, wherein the third swellable material chamber and the contact assembly of the fourth movable arm substantially surround the third swellable material, wherein the fourth movable arm or a portion thereof is configured to rotate about a second axis by sliding the contact assembly along the fourth directional channel, such that the fourth movable arm extends into or further out of the body of the oral dosage form, one or more fluid inlets operably connected to the third swellable material chamber; and a drug, wherein the oral dosage form is configured to have a pre-dose state in a compact form and a post-dose state in a deployed form providing gastric retention, and wherein the deployed form of the post-dose state of the oral dosage form is at least partially due to the swelling of the first swellable material, the second swellable material, and the third swellable material in the presence of gastrointestinal fluid.;

[0073] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm is extendable beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the swellable material, wherein the first movable arm and the second movable arm are configured to rotate in opposite directions about a shared axis; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a first guiding channel and a second guiding channel operatively connected to the swellable material chamber, wherein the first guiding channel and the second guiding channel are curved and configured about the shared axis, wherein the first movable arm comprises a first contact assembly configured to contact the swellable material proximate to the first guiding channel, wherein the first contact assembly is rudder-shaped and configured to travel in the first guiding channel such that the first movable arm rotates relative to the shared axis beyond or further from the body of the oral pharmaceutical dosage form, wherein the second movable arm comprises a second contact assembly configured to contact the swellable material proximate to the second guiding channel, wherein the second contact assembly is rudder-shaped and configured to travel in the second guiding channel such that the second movable arm rotates relative to the shared axis beyond or further from the body of the oral pharmaceutical dosage form, one or more fluid inlets operatively connected to the swellable material chamber; a stopper configured to engage the first movable arm and the second movable arm in an extended position; a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form providing gastric retention, and wherein the expanded form of the post-administration state of the oral pharmaceutical dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0074] In other aspects, provided herein is an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction towards a plane of vertical position along an independent axis by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or an orifice operatively connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material proximate to the orienting channel and / or the orifice, and wherein the swellable material chamber, the contact assemblies of the movable arms, and a lid substantially surround the swellable material; one or more fluid inlets operatively connected to the swellable material chamber; a lid; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post-administration state of the oral dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0075] In other aspects, provided herein is an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction towards a plane of vertical position along an independent axis by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or an orifice operatively connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material proximate to the orienting channel and / or the orifice, and wherein the swellable material chamber and the contact assemblies of the movable arms substantially surround the swellable material; one or more fluid inlets operatively connected to the swellable material chamber; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post-administration state of the oral dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0076] In other aspects, provided herein is an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material, wherein the swellable material is at least partially encapsulated by a semipermeable membrane; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates along an independent axis in a direction toward a vertical plane of position by a force provided by the swellable material; and comprising: a first connection point of the first arm, a second connection point of the second arm, a third connection point of the third arm, and a fourth connection point of the fourth arm, wherein each connection point is configured to provide an independent axis for rotation of the first arm, the second arm, the third arm, and the fourth arm, wherein each movable arm includes a contact assembly configured to contact the swellable material or the semipermeable material, and a first stop, a second stop, a third stop, and a fourth stop, the stops being configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm, respectively, in an extended position, wherein the oral dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form that provides gastric retention, and wherein the expanded form of the post - dosing state of the oral dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0077] In other aspects, provided herein is a swelling structure for an oral dosage form, the swelling structure comprising: a swellable material; a housing comprising: an outer shell comprising at least two layers, wherein at least two layers have successively smaller outer dimensions, wherein at least two layers are configured to have a pre - dosing state in a compact form, wherein at least two of the at least two layers slide along an axis, wherein at least two layers extend along an axis and are configured to have a post - dosing state in an extended form, wherein the post - dosing state in an extended form provides gastric retention, one or more fluid inlets operably connected to a chamber of the swellable material; wherein the swelling of the swelling structure is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0078] In other aspects, provided herein is an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: an expandable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction along an independent axis in a vertical plane of position by a force provided by the expandable material; a body comprising: an expandable material chamber configured to contain at least a portion of the expandable material; an orienting channel and / or an orifice operatively connected to the expandable material chamber, wherein each movable arm includes a contact assembly configured to contact the expandable material adjacent to the orienting channel and / or the orifice, and wherein the expandable material chamber, the contact assemblies of the movable arms, and a lid substantially surround the expandable material; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage with the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form providing gastric retention, and wherein the expanded form of the post - dosing state of the oral pharmaceutical dosage form is at least in part due to the expansion of the expandable material in the presence of gastrointestinal fluid. I. Definitions

[0079] For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural and vice versa. If any of the following definitions conflict with any document incorporated herein by reference, the definitions set forth herein will control.

[0080] As used herein, the term "individual" refers to a mammal, including but not limited to a human, bovine, equine, feline, canine, rodent, rat, mouse, dog, or primate. In some embodiments, the individual is a human individual.

[0081] The terms "comprising", "having", "containing", and "including" and other similar forms and their grammatical equivalents as used herein are intended to be equivalent in meaning and are open - ended, in that none of these words with one or more items is meant to be an exhaustive list of such one or more items or limited to the listed one or more items. For example, an article "containing" components A, B, and C may consist of (i.e., only contain) components A, B, and C, or may contain not only components A, B, and C but also one or more other components. Thus, it is intended and understood that "including" and its similar forms, and their grammatical equivalents, include the disclosure of embodiments "consisting essentially of" or "consisting of".

[0082] In the case of providing a series of values, it is understood that, unless the context clearly dictates otherwise, each intervening value between the upper and lower limits of the range and any other stated or intervening value within the stated range is included within the disclosure, subject to any explicit exclusions of limitations within the stated range. Ranges that do not include one or both of the included limits, if the stated range includes one or both of the limits, are also included in the disclosure.

[0083] References herein to a value or parameter “about” include (and describe) variations that refer to the value or parameter itself. For example, a description that refers to “about X” includes a description of “X”.

[0084] As used herein, including in the appended claims, the singular forms “a,” “an,” “or,” and “the” include plural referents unless the context clearly dictates otherwise. II. Oral Dosage Forms for Gastric Retention

[0085] In some aspects, the present disclosure is directed to dosage forms that are designed to provide desired retention in an individual based on geometric differences between the state of the dosage form before and after administration, e.g., a change in size in one or more dimensions. In some aspects of the description provided herein, oral dosage forms are exemplified; however, it should be understood that the teachings of such dosage forms can be readily extrapolated to other dosage forms, such as dosage forms suitable for vaginal or rectal administration. In some aspects, provided herein are oral dosage forms for gastric retention and their components. The oral dosage forms provided herein are configured with a swellable material, including one or more portions of swellable material composed of the same or different substances, such that the swellable material swells upon exposure to gastrointestinal fluid and provides a force that drives a mechanical device to increase the size of the oral dosage form. The increase in the size of the oral dosage form results in the oral dosage form remaining in the stomach for a longer period of time because it cannot easily pass through the pylorus.

[0086] In some embodiments, the dosage form or its components swell due to body fluid. For example, in some embodiments, the body fluid is gastrointestinal fluid.

[0087] In some embodiments, provided is an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm can extend beyond or further from the body of the oral dosage form by a force provided by the swellable material; and a body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a directional channel and / or an orifice operatively connected to the swellable material chamber, wherein the movable arm includes a contact assembly configured to contact the swellable material or a feature associated with the swellable material when located near the directional channel and the orifice; and one or more fluid inlets operatively connected to the swellable material chamber; and a drug, wherein the oral dosage form is configured to have a pre - administration state in a compact form and a post - administration state in a deployed form providing gastric retention, and wherein the deployed form of the post - administration state of the oral dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the drug is located in one or more of the one or more movable arms or the body (or its components, such as the lid).

[0088] In some embodiments, the swellable material is a chemical composition; in some embodiments, the swellable material chamber includes a chemical composition and a plunger structure, wherein the plunger structure has a certain rigidity and the swelling composition pushes it towards the orifice, thereby pushing the movable arm to deploy; in some embodiments, the piston is pushed beyond the orifice; in some embodiments, the piston moves in the direction of the orifice until blocked by the lid; in some embodiments, the plunger structure is a piston having a greater rigidity than the swelling composition.

[0089] In some embodiments, an oral dosage form for gastric retention is provided, the oral dosage form comprising: a swellable material, wherein the swellable material is at least partially encapsulated by a semipermeable membrane; in some embodiments, the body or substrate is entirely a semipermeable membrane; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction towards a vertically placed plane along an independent axis by a force provided by the swellable material; a body comprising: a first connection point for the first arm, a second connection point for the second arm, a third connection point for the third arm, and a fourth connection point for the fourth arm, wherein each connection point is configured to provide an independent axis for the rotation of the first arm, the second arm, the third arm, and the fourth arm, wherein each movable arm comprises a contact assembly configured to contact the swellable material or the semipermeable material, and a first stop, a second stop, a third stop, and a fourth stop, the stops being configured to engage with the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position, wherein the oral dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

[0090] As described herein, the oral dosage form includes movable components, such as those involved in the transition between a pre - administration state (e.g., a compact state for oral administration purposes) and a post - administration state (e.g., an expanded state for gastric retention purposes). Thus, there may be some differences between the most compact and the most expanded states that the oral dosage form attains during use. The description of a single pre - administration state and a single post - administration state is not intended to limit the scope of the description provided herein, and as taught herein, during the dosing lifecycle, the oral dosage form may experience multiple pre - administration states and / or multiple post - administration states. Additionally, the oral dosage form provided herein is configured to eventually be cleared from the stomach of the individual to whom the oral dosage form is administered.

[0091] Additional sections are provided below to teach example mechanisms related to providing gastric retention by the oral dosage form, as well as certain aspects of the oral dosage form. This modular description is not intended to limit the scope of the description provided herein, and based on the teachings provided herein, one of ordinary skill in the art will readily understand that the description includes any combination of modules assembled together to form an oral dosage form with gastric retention. A. Examples of Oral Dosage Forms

[0092] To illustrate and explain the subject matter provided herein, certain pharmaceutical dosage forms are described below, such as oral pharmaceutical dosage forms. As previously mentioned, the basic teachings described herein enable various movable arm devices to provide an increase in the size of an oral pharmaceutical dosage form such that the oral pharmaceutical dosage form does not readily pass through the pylorus during a desired time period, thereby exhibiting a gastric retention period. In certain aspects, the oral pharmaceutical dosage forms taught herein include a single teaching for size increase after administration. In some embodiments, two or more instances of a single mechanism, such as a sliding arm, can be used for a single oral pharmaceutical dosage form. In certain aspects, the oral pharmaceutical dosage forms taught herein include more than one teaching mechanism for size increase after administration, such as using two styles of movable arms.

[0093] An example of an oral pharmaceutical dosage form 100 for gastric retention is provided in Figures 1A - 1C . In the pre - administration state as shown in Figure 1A , the oral pharmaceutical dosage form 100 includes a swellable material chamber 106 containing a swellable material 102, and the swellable material chamber 106 is formed by a body 104 formed by the oral pharmaceutical dosage form 100. The oral pharmaceutical dosage form 100 includes a movable arm 108 that is located inside (or substantially inside) the oral pharmaceutical dosage form 100 in the pre - administration state. The movable arm 108 is configured such that at least a portion of the movable arm extends beyond or further from the body 104 of the oral pharmaceutical dosage form 100 by a force that can be provided by the swellable material 102. The body 104 of the oral pharmaceutical dosage form 100 forms a guiding channel 110 that is configured to guide the movement of the movable arm 108 when the swellable material 102 swells. In the pre - administration state, the oral pharmaceutical dosage form 100 is designed such that the movable arm 108 includes a contact assembly 112 that is configured to come into contact with the swellable material 102 near the guiding channel 110. When the swellable material 102 swells, the swellable material 102 will push the contact assembly 112 of the movable arm 108 to move the movable arm 108. The body 104 also forms a stop 114 that is configured to engage the movable arm 108 in an extended position. The post - administration state of the oral pharmaceutical dosage form 100 is as shown in Figure 1B . In the post - administration state, gastrointestinal fluid has entered the oral pharmaceutical dosage form 100 such that the swellable material 102 swells and pushes the movable arm 108 through the guiding channel 110 to the stop 114. A component view of the oral pharmaceutical dosage form 100 is provided in Figure 1C . As shown in Figure 1CAs shown, the body 104 of the oral pharmaceutical dosage form 100 can include a frame 116 and caps 118, 120. In certain embodiments, the frame 116 or a portion thereof includes a semipermeable material that allows gastrointestinal fluid to contact the swellable material. In some embodiments, the semipermeable material provides access of gastrointestinal fluid to the swellable material chamber 106. In some embodiments, the semipermeable material provides access of gastrointestinal fluid to the directional channel 110 such that the swellable material can continue to absorb gastrointestinal fluid during swelling. In some embodiments, the oral pharmaceutical dosage form can include one or more fluid inlets, wherein at least one fluid inlet is a pore. A component view of the oral pharmaceutical dosage form 100 is provided in Figure 1D as shown in Figure 1C . As shown, certain oral pharmaceutical dosage forms can have a seamless transition between the swellable material chamber and the directional channel, where a boundary can be designated for descriptive purposes, which is consistent with the teachings provided herein. In some embodiments, the components of the oral pharmaceutical dosage form 100 can be produced and prepared, for example, by methods such as three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral pharmaceutical dosage form 100 before administration. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of the movable arm, and these components are then assembled to form the oral pharmaceutical dosage form.

[0094] An example of an oral pharmaceutical dosage form 200 for gastric retention is provided in Figures 2A - 2C as shown in Figure 2A . In the pre-administration state as shown, the oral pharmaceutical dosage form 200 includes a swellable material chamber 206 containing a swellable material 202, which is formed by the body 204 of the oral pharmaceutical dosage form 200. The oral pharmaceutical dosage form 200 includes a movable arm 208 that is located (or substantially within) the interior of the oral pharmaceutical dosage form 200. The movable arm 208 is configured such that at least a portion of the movable arm extends beyond or further from the body 204 of the oral pharmaceutical dosage form 200 by a force that can be provided by the swellable material 202. The body 204 of the oral pharmaceutical dosage form 200 forms a directional channel 210 that is configured to guide the movement of the movable arm 208 when the swellable material 202 swells. In the pre-administration state, the oral pharmaceutical dosage form 200 is designed such that the movable arm 208 includes a contact assembly 212 that is configured to be at the interface of the swellable material 202 near the directional channel 210. When the swellable material 202 swells, the swellable material 202 will push the contact assembly 212 of the movable arm 208 to move the movable arm 208. The body 204 also forms a stop 214 that includes a locking assembly that is configured to hold the movable arm 208 in the extended position in the post-administration state. The post-administration state of the oral pharmaceutical dosage form 200 is as shown in Figure 2BAs shown. In the post - administration state, gastrointestinal fluid has entered the oral drug dosage form 200, causing the swellable material 202 to swell and push the movable arm 208 through the directional channel 210 to the stop 214 that includes the locking assembly. As Figure 2B shown, a portion of the movable arm 208 engages with the locking assembly such that the movable arm 208 remains in the extended position (inhibiting substantial movement in the direction of movement of the movable arm in the directional channel or in the opposite direction). A component view of the oral drug dosage form 200 is shown in Figure 2C . As Figure 2C shown, the body 204 of the oral drug dosage form 200 can include a frame 216 and caps 218, 220. In certain embodiments, the frame 216 or a portion thereof comprises a semi - permeable material that allows gastrointestinal fluid to contact the swellable material. In some embodiments, the semi - permeable material provides access of gastrointestinal fluid to the swellable material chamber 206. In some embodiments, the semi - permeable material provides a directional channel 210 for gastrointestinal fluid such that the swellable material can continue to absorb gastrointestinal fluid during the swelling process. In some embodiments, the oral drug dosage form can include one or more fluid inlets, where at least one fluid inlet is a pore. A component view of the body 204 and the movable arm 208 is provided in Figure 2D . As Figure 2C shown, certain oral drug dosage forms can have a seamless transition between the swellable material chamber and the directional channel, where a boundary can be specified for descriptive purposes, consistent with the teachings provided herein. In some embodiments, the components of the oral drug dosage form 200 can be produced, for example, by methods such as three - dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral drug dosage form 200 before administration. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of the movable arm, and these components are then assembled to form the oral drug dosage form.

[0095] As Figure 2E and 2F shown, variant designs of the oral drug dosage form 200 are provided. Specifically, Figure 2E and 2F the oral drug dosage form 250 provided therein has a different locking assembly 264, where the locking assembly 264 engages unilaterally with the movable arm 260. The body 254 of the oral drug dosage form 250 forms a swellable material chamber 256, a directional channel 258, and a stop including the locking assembly 264. The swellable material 252 is contained in the swellable material chamber 256. A contact surface 262 is configured on the movable arm 260. In Figure 2F the post - administration state, the swellable material 252 has pushed the movable arm 260 to the extended position through the contact surface 262 such that the movable arm 260 engages the locking assembly 264 of the stopped oral drug dosage form 250. Figure 2GA component view of the body 254 and the movable arm 260 is provided.

[0096] In Figure 3A and 3B Examples of oral dosage forms 300 for gastric retention are provided. As Figure 3A shown in the pre - administration state, the oral dosage form 300 includes a swellable material chamber 306 containing a swellable material 302, and the swellable material chamber 306 is formed by the oral dosage form 304. The oral dosage form 300 includes a movable arm 308 which, in the pre - administration state, is located inside (or substantially inside) the oral dosage form 300. The movable arm 308 is configured such that at least a portion of the movable arm can be extended beyond or further from the body 304 of the oral dosage form 300 by the force provided by the swellable material 302. The body 304 of the oral dosage form 300 forms a guiding channel 310 which is configured to direct the movement of the movable arm 308 when the swellable material 302 swells. In the pre - administration state, the oral dosage form 300 is designed such that the movable arm 308 includes a contact assembly 312 which is configured to interface with the swellable material 302 near the guiding channel 310. When the swellable material 302 swells, the swellable material 302 will push the contact assembly 312 of the movable arm 308 to move the movable arm 308. The body 304 also forms a stop 314 which includes a locking assembly configured to hold the movable arm 308 in the extended position in the post - administration state. The post - administration state of the oral dosage form 300 is as Figure 3B shown. In the post - administration state, gastrointestinal fluid has entered the oral dosage form 300 such that the swellable material 302 swells and pushes the movable arm 308 via the guiding channel 310 to the stop 314 which includes the locking assembly. As Figure 3B shown, the locking assembly includes a number of steps which can engage with the movable arm at various extended positions, and in some embodiments, the post - administration state can be a stop at any one or more of the extended positions provided by the several steps of the locking assembly. As Figure 3B shown, a portion of the movable arm 308 engages with the locking assembly such that the movable arm 308 is held in the extended position (substantial movement in the direction of movement of the movable arm in the guiding channel or the opposite direction is inhibited; however, it should be noted that for the steps prior to the final one, movement is allowed to permit further extension to the most extended step of the locking assembly). A component view of the oral dosage form 300 is shown in Figure 3C .

[0097] Examples of oral dosage forms 400 for gastric retention are provided in Figures 4A - 4C As Figure 4AThe pre - administration state shown, the oral drug dosage form 400 includes a swellable material chamber 406 containing a swellable material 402, and the swellable material chamber 406 is formed by a body 404 of the oral drug dosage form 400. The oral drug dosage form 400 includes a first movable arm 408, which is located (or substantially within) the interior of the oral drug dosage form 400. The movable arm 408 is configured such that at least a portion of the movable arm extends beyond or further from the body 404 of the oral drug dosage form 400 by the force provided by the swellable material 402. The body 404 of the oral drug dosage form 400 forms a guiding channel 410, which is configured to guide the movement of the movable arm 408 when the swellable material 402 swells. In the pre - administration state, the oral drug dosage form 400 is designed such that the movable arm 408 includes a contact assembly 412, which is configured to interface with the swellable material 402 near the guiding channel 410. The oral drug dosage form 400 includes a plurality (as shown in FIG. 4) of fluid inlets operably connected to the swellable material chamber 406 in the form of holes 416. When the swellable material 402 swells, the swellable material 402 will push the contact assembly 412 of the movable arm 408 to move the movable arm 408. The body 404 also forms a stop 414 for stopping the movable arm 408 at the extended position in the post - administration state. The oral drug dosage form 400 also includes a second movable arm 418, which has a contact assembly 420, which is configured to contact the swellable material 402. The second movable arm 418 is configured relative to a second guiding channel 422, wherein the second movable arm 418 will move to a stop 424 in the second guiding channel 422. The post - administration state of a portion of the oral drug dosage form 400 is as Figure 4B shown. In the post - administration state, gastrointestinal fluid enters the oral drug dosage form 400 through the fluid inlets containing the holes 416, causing the swellable material 402 to swell and push the first movable arm 408 and the second movable arm 418 to their respective stops 414, 424, such that the first movable arm 408 and the second movable arm 418 remain in the extended position. Component views of the oral drug dosage form 400 are provided in Figure 4C and 4D . As Figure 4C shown, certain oral drug dosage forms can have a seamless transition between the swellable material chamber and the guiding channel, where boundaries can be specified for descriptive purposes, which is consistent with the teachings provided herein. In some embodiments, the components of the oral drug dosage form 400 can be produced, for example, by methods such as three - dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the pre - administration oral drug dosage form 400. For example, in some embodiments, the body (or one or more portions thereof) is produced independently of the first and second movable arms, and these components are then assembled to form the oral drug dosage form.

[0098] An example of an oral pharmaceutical dosage form 500 for gastric retention is provided in Figures 5A - 5F . As shown in the pre - administration state of Figure 5A , the oral pharmaceutical dosage form 500 includes a first swellable material chamber 506 containing a first swellable material 502, and the first swellable material chamber 506 is formed by a body 504 of the oral pharmaceutical dosage form 500. The oral pharmaceutical dosage form 500 includes a first movable arm 508, which is located (or substantially within) the interior of the oral pharmaceutical dosage form 500. The first movable arm 508 is configured such that at least a portion of the first movable arm can be extended beyond or further from the body 504 of the oral pharmaceutical dosage form 500 by the force provided by the first swellable material 502. The body 504 of the oral pharmaceutical dosage form 500 forms a first guiding channel 510, which is configured to guide the movement of the first movable arm 508 when the first swellable material 502 swells. In the pre - administration state, the oral pharmaceutical dosage form 500 is designed such that the first movable arm 508 includes a contact assembly 512, which is configured to contact the first swellable material 502 near the first guiding channel 510. The oral pharmaceutical dosage form 500 includes a plurality (four as shown in the figure) of fluid inlets in the form of holes 516, which are operably connected to the first swellable material chamber 506. As the first swellable material 502 swells, the first swellable material 502 pushes the contact assembly 512 of the first movable arm 508 to move the first movable arm 508. The first guiding channel includes a plurality (four as shown in the figure) of fluid inlets in the form of holes 518, which are operably connected to the first guiding channel 510, such that when the first movable arm 508 passes through the first guiding channel 510, the first swellable material 502 continues to be exposed to gastrointestinal fluids. The body 504 also forms a first stop 514, which is configured to stop the first movable arm 508 in the extended position in the post - administration state. The oral pharmaceutical dosage form 500 also includes a second movable arm 520 having a movement mechanism that matches the first movable arm 508. Both the first movable arm and the second movable arm are configured to rotate about an axis (e.g., 522 for the second movable arm 520). The post - administration state of the oral pharmaceutical dosage form 500 is shown in Figure 5B . In the post - administration state, gastrointestinal fluids enter the oral pharmaceutical dosage form 500 via fluid inlets including holes (e.g., 516 and 518 related to the first swellable material), such that the swellable material (e.g., the first movable arm 508 related to the first swellable material 502) pushes the movable arms 508, 520 to their respective stops (e.g., the first stop 514 related to the first movable arm 508), such that the first movable arm 508 and the second movable arm 520 are configured in the deployed position. Additional pre - administration and post - administration state views of the oral pharmaceutical dosage form 500 are provided in Figure 5C and Figure 5D respectively. As shown in Figure 5C andFigure 5D As shown, the body 504 of the oral pharmaceutical dosage form 500 can include a frame 524 and a lid 526. Component views and accompanying schematic diagrams of certain aspects of the oral pharmaceutical dosage form 500 are provided in Figure 5E and 5F As provided in Figure 5E As shown in the frame view 524, certain oral pharmaceutical dosage forms can have a seamless transition between a swellable material chamber and a directional channel, where boundaries can be specified, for illustrative purposes, in accordance with the teachings provided herein. In some embodiments, the components of the oral pharmaceutical dosage form 500 can be prepared, for example, by methods such as three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral pharmaceutical dosage form 500 prior to administration. For example, in some embodiments, the body (or one or more portions thereof) is produced independently of the first movable arm and the second movable arm, and these components are subsequently assembled to form the oral pharmaceutical dosage form.

[0099] As taught herein, the oral pharmaceutical dosage form can include movable arms configured to include different movement mechanisms. An example of an oral pharmaceutical dosage form 600 for gastric retention is provided in Figures 6A - 6H As provided in Figure 6AIn the pre - administration state shown, the oral drug dosage form 600 includes a body 602 that includes a first swellable material 604 within a first swellable material chamber 606. The body 602 includes a first fluid inlet that includes pores 608 (four as shown in the figure) operatively connected to the first swellable material chamber 606. The body 602 includes a first directional channel 610 and a second directional channel 612 that are operatively connected to the first swellable material chamber 606. A first movable arm 614 is located within the first directional channel 610 and a second movable arm 616 is positioned within the second directional channel 612. The oral drug dosage form 600 is configured in the pre - administration state such that the first movable arm 614 and the second movable arm 616 are located inside (or substantially inside) the oral drug dosage form 600. The first movable arm 614 and the second movable arm 616 are configured such that they can extend outside or further beyond the body 602 of the oral drug dosage form 600 by the force provided by the first swellable material 604. The first directional channel 610 and the second directional channel 612 are configured to guide the movement of the first movable arm 614 and the second movable arm 616 respectively when the first swellable material 604 swells. The body 602 of the oral drug dosage form 600 further includes a second swellable material 618 within a second swellable material chamber 620. The body 602 includes a second set of fluid inlets that includes holes 622 (two in the figure) operatively connected to the second swellable material chamber 620. The body 602 includes a third directional channel 634 operatively connected to the second swellable material chamber 620. A third movable arm 630 is located within the third directional channel 634. The oral drug dosage form 600 is configured in the pre - administration state such that the third movable arm 630 is located inside (or substantially inside) the oral drug dosage form 600. The third movable arm 630 is configured to be extendable outside or further beyond the body 602 of the oral drug dosage form 600 by the force provided by the second swellable material 618. The third directional channel 634 is configured to guide the movement of the third movable arm 630 when the second swellable material 618 swells. The body 602 of the oral drug dosage form 600 further includes a third swellable material 624 within a third swellable material chamber 626. The body 602 includes a third set of fluid inlets that includes pores 628 (two as shown in the figure) operatively connected to the third swellable material chamber 626. The body 602 includes a fourth directional channel 636 operatively connected to the third swellable material chamber 626. A fourth movable arm 632 is located within the fourth directional channel 636. The oral drug dosage form 600 is configured in the pre - administration state such that the fourth movable arm 632 is located inside (or substantially inside) the oral drug dosage form 600. The fourth movable arm 632 is configured to be extendable outside or further beyond the body 602 of the oral drug dosage form 600 by the force provided by the third swellable material 624.The fourth orienting channel 636 is configured to direct the movement of the fourth movable arm 632 when the third swellable material 624 swells. In. Figure 6B Another view of the pre - dosing state of the oral dosage form 600 is provided, where only certain features are labeled to guide points for understanding the features of the oral dosage form 600. The post - dosing state of the oral dosage form 600 is as Figure 6C shown, showing the extended positions of the first movable arm 614, the second movable arm 616, the third movable arm 630, and the fourth movable arm 632 outside the oral dosage form 602. Another view of the post - dosing state of the oral dosage form 600 is in Figure 6D provided, where only certain features are labeled to guide for understanding the features of the oral dosage form 600. A component view and a schematic view of the oral dosage form 600 are in Figures 6E - 6H provided. As Figure 6E and 6F shown, the body 602 can consist of two or more modules, such as 602a and 602b. Figure 6E The body 602a associated with the first and second movable arms is shown. Figure 6F The body 602b associated with the third and fourth movable arms is shown. Figure 6G A view and a schematic view of the first and second movable arms are shown. Figure 6H A view and a schematic view of the third and fourth movable arms are shown. In some embodiments, the components of the oral dosage form 600 can be produced, for example, by three - dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the pre - dosing oral dosage form 600. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of the first and second movable arms, and these components are then assembled to form the oral dosage form.

[0100] Examples of oral dosage forms 700 are shown in Figures 7A - 7I . As Figure 7A and 7B shown, in the pre - dosing state, the oral dosage form 700 includes a body 702, a first movable arm 704, and a second movable arm 706 to form a capsule - shaped oral dosage form. The post - dosing state of the oral dosage form 700 is as Figure 7CAs shown, the positions of the first movable arm 704 and the second movable arm 706 are both outside or far from the main body 702 of the oral pharmaceutical dosage form 700. In the post - administration state view, a set of fluid inlets in the form of pores 710 are shown on the main body 702, and these fluid inlets are operatively connected to a swellable material chamber 708 containing at least a portion of a swellable material. To illustrate the mechanism of the oral pharmaceutical dosage form 700, a cross - sectional view of the pre - administration state of the oral pharmaceutical dosage form 700 is provided and further discussed ( Figure 7D ), and a cross - sectional view of the post - administration state ( Figure 7E ). As shown in Figure 7D , the main body 702 of the oral pharmaceutical dosage form 700 includes a swellable material chamber 708, a first directional channel 718, and a second directional channel 724. The swellable material chamber 708 includes a swellable material 714. In Figure 7D , the first arm (not fully shown) includes a rudder - shaped feature 716 that is configured to travel in the first directional channel 718, and the rudder - shaped feature 716 includes a contact assembly 720 that is configured to contact the swellable material 714. As further shown in Figure 7D , the second arm (not fully shown) includes a rudder - shaped feature 722 that is configured to travel in the second directional channel 724, and the rudder - shaped feature 722 includes a contact assembly 726 that is configured to contact the swellable material 714. As shown in Figure 7E , in the post - administration state, the swellable material 714 has swollen into the first directional channel 718 and the second directional channel 724 and exerts a force on the first movable arm and the second movable arm through each respective rudder - shaped feature. The oral pharmaceutical dosage form 700 is configured such that the first movable arm and the second movable arm rotate along axis 730 until they reach the stop 728. Specifically, the rudder - shaped feature 716 of the first movable arm and the rudder - shaped feature 722 of the second movable arm travel in their respective directional channels, causing the respective movable arms to extend out or further away from the main body 702 of the oral pharmaceutical dosage form 700. Additional views of the oral pharmaceutical dosage form 700 are provided in Figure 7F , showing the first movable arm 704 and the second movable arm 706 in the extended post - administration state, where the rudder - shaped feature 716, the first movable arm 722, and the second movable arm 706 are pushed by the swellable material 714 into contact with the stop 728. The size of the oral pharmaceutical dosage form 700 in the post - administration state provides gastric retention because the increased size is not easily passed through the pylorus. A component view and schematic diagrams of various aspects of the oral pharmaceutical dosage form 700 are provided in Figures 7G - 7Iprovided in. In some embodiments, the components of the oral pharmaceutical dosage form 700 can be produced and prepared, for example, by methods such as three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral pharmaceutical dosage form 700 before administration. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of the first movable arm and the second movable arm, and these components are then assembled to form the oral pharmaceutical dosage form.

[0101] An example of a dosage form with four movable arms is provided in Figures 8A - 8I provided in. The pre-administration state of the oral pharmaceutical dosage form 800 is provided in Figure 8A provided in, wherein the oral pharmaceutical dosage form 800 includes a body 802 having a swellable material chamber 804 configured to contain at least a portion of the swellable material 810. The body includes a set of fluid inlets 808 operatively connected to the swellable material chamber 804. The body 802 includes a directional channel 806 operatively connected to the swellable material chamber 804, wherein, upon swelling, the swellable material 810 can swell in the direction guided by the directional channel 806. The swellable material 810 can be configured with non-swelling features, such as maintaining a certain shape of at least a portion of the swellable material and / or contacting a contact component of one or more movable arms. As Figure 8A shown, in the pre-administration state, the swellable material is embedded in non-swelling features covering the upper part of the swellable material (as shown later Figure 8C shown, the non-swelling features 828 covering the upper part of the swellable material 810 have been pushed upward and contact each movable arm). The body of the oral pharmaceutical dosage form 800 includes a lid 812. The oral pharmaceutical dosage form 800 includes four movable arms ( Figure 8A the view of shows three movable arms 814, 816, 818), and at least a portion of each movable arm can be extended beyond or further from the body of the oral pharmaceutical dosage form 800 by the force provided by the swellable material 810. Specifically, each movable arm is configured to rotate about an axis. For example, the first movable arm 814 is configured to rotate about a first axis 824. The movable arm can include a feature 826 configured to engage a stop of the oral pharmaceutical dosage form 800. As Figure 8A shown in the pre-administration state, the oral pharmaceutical dosage form can also include an erodible restraint 822 configured to inhibit the extension of the movable arm in the pre-administration state. Figure 8B The oral pharmaceutical dosage form 800 shown in does not have an erodible restraint, which can be an embodiment of the pre-administration state of the oral pharmaceutical dosage form 800 or the post-administration state of the oral pharmaceutical dosage form 800, wherein the erodible restraint has been eroded, but the movable arm has not moved to the extended position. A cross-sectional view of the oral pharmaceutical dosage form 800 is provided in Figure 8Cis provided, wherein the swellable material 810 swells under the guidance of the directional channels 806 of the body 802 (by the non-swellable feature 828 covering the upper part of the swellable material 810) such that each movable arm moves to an extended position until it reaches the stop 826. Figure 8D A top view showing the state of the oral drug dosage form 800 after administration is provided, wherein the first movable arm 814, the second movable arm 816, the third movable arm 818, and the fourth movable arm 820 are all shown in the extended position. Schematic views of the components and various aspects of the oral drug dosage form 800 are provided in Figures 8E - 8I is provided. In some embodiments, the components of the oral drug dosage form 800 can be produced and prepared, for example, by methods such as three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral drug dosage form 800 before administration. For example, in some embodiments, the body (or one or more parts thereof, such as the lid 812) is produced independently of each movable arm, and these components are then assembled to form the oral drug dosage form.

[0102] An example of a dosage form having four movable arms is provided in Figures 9A - 9I is provided. The state of the oral drug dosage form 900 before administration is provided in Figure 9A is provided, wherein the oral drug dosage form 900 includes a body 902 having a swellable material chamber 904 configured to contain at least a portion of the swellable material 910. The body includes a set of fluid inlets 908 operatively connected to the swellable material chamber 904. The body 902 includes an orifice 906 operatively connected to the swellable material chamber 904, wherein, upon swelling, the swellable material 910 can protrude and extend beyond the orifice 906 (or at least to a greater extent the swellable material has protruded through the orifice). The swellable material 910 can be configured with non-swellable features, such as maintaining a certain shape of at least a portion of the swellable material and / or contacting a contact assembly of one or more movable arms. As Figure 9A shown, in the state before administration, the swellable material is embedded in the non-swellable feature covering the upper part of the swellable material (as shown later in Figure 9C ), and the non-non-swellable feature 928 covering the upper part of the swellable material 910 is pushed upward and contacts each movable arm. The body of the oral drug dosage form 900 includes a lid 912. The oral drug dosage form 900 includes four movable arms ( Figure 9A 's view shows three movable arms 914, 916, 918), and at least a portion of each movable arm can be extended outside or further from the body of the oral drug dosage form 900 by the force provided by the swellable material 910. Specifically, each movable arm is configured to rotate about an axis. For example, the first movable arm 914 is configured to rotate about a first axis 924. As Figure 9AIn the pre - administration state shown, the oral pharmaceutical dosage form 900 may further include an erodible restraint 922 configured to inhibit the extension of the movable arms in the pre - administration state. Figure 9B The illustrated oral pharmaceutical dosage form 900 does not have an erodible restraint, which can be an embodiment of the pre - administration state of the oral pharmaceutical dosage form 900 or the post - administration state of the oral pharmaceutical dosage form 900, where the erodible restraint has been eroded but the movable arms have not yet moved to the extended position. A cross - sectional view of the oral pharmaceutical dosage form 900 is provided in Figure 9C wherein the swellable material 910 has swollen and exerted a force (through the non - swellable feature 928 covering the upper portion of the swellable material 910) on each movable arm over (at least in part) the orifice 906 of the body 902, causing each movable arm to move to an extended position. Figure 9D A top view of the post - administration state of the oral pharmaceutical dosage form 900 is shown, where the first movable arm 914, the second movable arm 916, the third movable arm 918, and the fourth movable arm 920 are all shown in the extended position. A component view and schematic diagrams of various aspects of the oral pharmaceutical dosage form 900 are provided in Figures 9E - 9I In some embodiments, the components of the oral pharmaceutical dosage form 900 can be produced, for example, by three - dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the pre - administration oral pharmaceutical dosage form 900. For example, in some embodiments, the body (or one or more parts thereof, such as the lid 912) is produced independently of each movable arm, and these components are then assembled to form the oral pharmaceutical dosage form.

[0103] An example of a dosage form having four movable arms is provided in Figures 10A - 10F The pre - administration state of the oral pharmaceutical dosage form 1000 is provided in Figure 10A wherein the oral pharmaceutical dosage form 1000 includes a body 1002 having a swellable material chamber 1004 configured to contain at least a portion of the swellable material 1010. The body includes a set of fluid inlets 1008 operatively connected to the swellable material chamber 1004. The body 1002 includes an orifice 1006 operatively connected to the swellable material chamber 1004, wherein, upon swelling, the swellable material 1010 can protrude and extend beyond (or at least to a greater extent if the swellable material has already protruded through the orifice) the orifice 1006. The swellable material 1010 can be configured with non - swellable features, such as maintaining a certain shape of at least a portion of the swellable material and / or contacting a contact assembly of one or more movable arms. As shown in Figure 10A the swellable material is embedded in the non - swellable feature, which encapsulates the swellable material in the pre - administration state (as shown later in Figure 10CAs shown, the non-swelling feature 1028 swells as the swellable material 1010 swells and contacts each movable arm). The non-swelling feature can be or include a semi-permeable material that permits gastrointestinal fluid to enter the swellable material. In some embodiments, an oral pharmaceutical dosage form can include one or more fluid inlets, where at least one fluid inlet is a pore. The oral pharmaceutical dosage form 1000 includes four movable arms ( Figure 10A The view of shows three movable arms 1014, 1016, 1018), and at least a portion of each movable arm is extendable beyond the body of the oral pharmaceutical dosage form 1000 or further by a force provided by the swellable material 1010. Specifically, each movable arm is configured to rotate about an axis. For example, the first movable arm 1014 is configured to rotate about a first axis 1024. As Figure 10A shown in the pre-administration state, the oral pharmaceutical dosage form 1000 can further include an erodible restraint 1022 that is configured to inhibit the extension of the movable arms in the pre-administration state. Figure 10B The oral pharmaceutical dosage form 1000 shown in does not have an erodible restraint, which can be an embodiment of the pre-administration state of the oral pharmaceutical dosage form 1000 or the post-administration state of the oral pharmaceutical dosage form 1000, where the erodible restraint has been eroded but the movable arms have not moved to the extended position. A cross-sectional view of the oral pharmaceutical dosage form 1000 is provided in Figure 10C where the swellable material 1010 has swollen and exerted a force (through the non-swelling feature, i.e., the semi-permeable material 1028 surrounding the swellable material 1010) on each movable arm over (at least in part) the orifice 1006 of the body 1002, causing each movable arm to move to an extended position. Figure 10D A top view of the post-administration state of the oral pharmaceutical dosage form 1000 is shown, where the first movable arm 1014, the second movable arm 1016, the third movable arm 1018, and the fourth movable arm 1020 are shown in the extended positions respectively. An assembly view of the swellable material 1010 surrounded by the non-swelling feature 1028 is provided for the pre-administration state ( Figure 10E ) and the post-administration state ( Figure 10F ). In some embodiments, the post-administration state forms a design shape provided by the swellable material and / or the non-swelling feature. In some embodiments, the components of the oral pharmaceutical dosage form 1000 can be produced, for example, by three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the pre-administration oral pharmaceutical dosage form 1000. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of each movable arm, and these components are then assembled to form the oral pharmaceutical dosage form.

[0104] An example of a dosage form having four movable arms is provided in Figures 11A - 11E The pre-administration state of the oral pharmaceutical dosage form 1100 is inFigure 11A is provided, wherein the oral dosage form 1100 includes a body 1102 that includes connection points for each of the movable arms. The oral dosage form 1100 includes four movable arms ( Figure 11A views of show three movable arms 1114, 1116, 1118), and at least a portion of each movable arm is extendable beyond or further from the body of the oral dosage form 1100 by a force provided by the swellable material 1110. Each movable arm is configured to rotate about an axis. For example, the first movable arm 1114 is configured to rotate about the first axis 1124. The swellable material 1110 may be configured with non-swelling features 1128, such as to maintain a certain shape of at least a portion of the swellable material and / or contact a contact assembly of one or more of the movable arms. As Figure 11A shown, the swellable material 1110 and associated non-swelling features 1128 are located between the top of the body 1102 and the movable arms. In some embodiments, the oral dosage form may include an erodible restraint around the movable arms. The non-swelling material 1128 associated with the swellable material 1110 is a semi-permeable material that allows gastric fluid to enter the swellable material. In some embodiments, the oral dosage form may include one or more fluid inlets, wherein at least one fluid inlet is a pore. A cross-sectional view of the oral dosage form 1100 is provided in Figure 11B wherein the swellable material 1110 has swollen and exerts a force (via the non-swelling features 1128) on each movable arm such that each movable arm moves to an extended position. Figure 11C shows a top view of the post-administration state of the oral dosage form 1100, wherein the first movable arm 1114, the second movable arm 1116, the third movable arm 1118, and the fourth movable arm 1120 are shown in the extended positions respectively. A component view and schematic diagrams of various aspects of the oral dosage form 1100 are provided in Figure 11D and Figure 11E In some embodiments, the components of the oral dosage form 1100 can be produced, for example, by three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral dosage form 1100 before administration.

[0105] As taught herein, in some embodiments, the swellable material (and optionally, any non-swelling features associated therewith) can have a desired pre-administration state and a desired post-administration state. For example, in certain dosage forms taught herein, provided are swellable materials (and optionally, any non-swelling features associated therewith) that obtain a particular structure in the post-administration state after swelling upon exposure to gastrointestinal fluids. An example of this concept is provided in the Figures 12A - 12E swelling structure 1200 of. In Figure 12AIn [description], the swellable material 1202 and the associated shell 1204 are shown in a pre - administration state in a side view, where the swellable material 1202 is the core within the associated shell 1204 that forms the swelling structure 1200. The shell 1204 is configured to expand into a shape having at least two layers with successively smaller outer dimensions. The associated shell 1204 includes means for water to enter the swellable material 1202, e.g., pores and / or semi - permeable materials. The top views of the swellable material 1202 and the associated shell 1204 are as shown in Figure 12B as shown. As can be seen from the top view of Figure 12B , four layers 1206, 1208, 1210, and 1212 are nested together in a concentric pre - administration state. Figure 12C and Figure 12D provide views of the post - administration state of the swelling structure 1200, where the swellable material 1202 has expanded to fill the associated shell 1204 such that the nested layers 1206, 1208, 1210, and 1212 expand to an expanded state. Additionally, Figure 12E and 12F provide views and schematic diagrams. Another example of the concept is provided in the swelling structure 1300 of Figures 13A - 13E . In Figure 13A , the swellable material 1302 and the associated shell 1304 are shown in a pre - administration state in a side view, where the swellable material 1302 is the base and protruding core within the associated shell 1304 that forms the swelling structure 1300. The shell 1304 is configured to expand to a shape having at least two layers with successively smaller outer dimensions. The associated shell 1304 includes means for water to enter the swellable material 1302, e.g., pores and / or semi - permeable materials. The top views of the swellable material 1302 and the associated shell 1304 are as shown in Figure 13B as shown. As can be seen from the top view of Figure 13B , four layers 1306, 1308, 1310, and 1312 are nested together in a concentric pre - administration state. Figure 13C and Figure 13D provide views of the post - administration state of the swelling structure 1300, where the swellable material 1302 has expanded to fill the associated shell 1304 such that the nested layers 1306, 1308, 1310, and 1312 expand to an expanded state. Additionally, Figure 13E and 13F provide views and schematic diagrams.

[0106] In Figure 14A and 14B , examples of dosage forms with four movable arms are provided, where the oral drug dosage form includes a column configured to push the movable arms by the force provided by the swellable material. The pre - administration state of the oral drug dosage form 1400 is shown in Figure 14Ais provided, wherein the oral pharmaceutical dosage form 1400 includes a body 1402 having a swellable material chamber 1404 configured to contain at least a portion of a swellable material 1410. The body includes a set of fluid inlets 1408 operatively connected to the swellable material chamber 1404. A column 1412 is located on top of the swellable material 1410. The body 1402 includes an aperture operatively connected to the swellable material chamber 1404, wherein, upon swelling, the swellable material 1410 pushes the column 1412 and at least a portion of the column can extend out and beyond the aperture. The oral pharmaceutical dosage form 1400 includes four movable arms ( Figure 14A The view of which shows four movable arms 1416, 1418, 1420, 1422), and at least a portion of each movable arm can be extended outside or further away from the body of the oral pharmaceutical dosage form 1400 by the force provided by the swellable material 1410. Specifically, each movable arm is configured to rotate about an axis. A cross-sectional view of the oral pharmaceutical dosage form 1400 is as shown in Figure 14B , wherein the swellable material 1410 has swollen and pushed the column 1412 to apply a force to each movable arm such that each movable arm moves to an extended position. In some embodiments, the components of the oral pharmaceutical dosage form 1400 can be produced, for example, by three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral pharmaceutical dosage form 1400 before administration. For example, in some embodiments, the body (or one or more portions thereof) is produced independently of each movable arm, and these components are then assembled to form the oral pharmaceutical dosage form.

[0107] An example of an oral pharmaceutical dosage form 1500 including four movable arms is shown in Figures 15A - 15D . As shown in Figure 15A , in the pre-administration state, the oral pharmaceutical dosage form 1500 includes a body 1502 forming two opposing outer portions of the pharmaceutical dosage form, wherein a first movable arm 1504 and a second movable arm 1506 are formed and visible in the view. As shown in Figure 15A , the body includes a first set of fluid inlets 1508, a second set of fluid inlets 1510, a first axis, and a second axis 1514. Figure 15BShows the state after administration, where the movable arms 1504, 1506, 1516, and 1518 have started to extend from the body 1502 of the oral drug dosage form 1500. After administration, the first set of fluid inlets allows gastrointestinal fluid to enter the swellable material chamber 1520 containing the swellable material. The third movable arm 1516 includes a rudder-shaped feature 1522 located in the guiding channel 1524, where, when the swellable material swells, the rudder-shaped feature 1522 is pushed through the guiding channel to extend the movable arm 1516 until it reaches the stop 1526. The first movable arm 1504 operates using this type of mechanism, and the first movable arm 1504 and the second movable arm 1516 rotate on a shared axis. The second movable arm 1506 and the fourth movable arm 1518 operate using this type of mechanism and rotate on the second axis 1514. Figure 15C Shows the state after administration of the oral drug dosage form 1500, where the movable arms are fully extended. Figure 15D Compositional views of various aspects of the oral drug dosage form 1500 are provided. In some embodiments, the components of the oral drug dosage form 1500 can be produced, for example, by three-dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral drug dosage form 1500 before administration. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of the first and second movable arms, and these components are then assembled to form the oral drug dosage form.

[0108] Figures 21A - 21C An example of a dosage form 2100 with four movable arms is provided. The state of the oral drug dosage form 2100 before administration is shown in Figure 21A where the oral drug dosage form 2100 includes a body 2102 having a swellable material chamber 2104 configured to contain at least a portion of the swellable material 2110. Similar to other teachings provided herein for oral drug dosage forms having a swellable material, in certain aspects, the swellable material can be used as a mechanism for changing the oral drug dosage form from the state before administration to the state after administration. In this embodiment, the body 2102 includes an orifice 2106 operatively connected to the swellable material chamber 2104, where, upon swelling, the swellable material 2110 can protrude and extend beyond the orifice 2106 (or at least to a greater extent the swellable material has protruded through the orifice). The swellable material 2110 can be configured with non-swelling features, such as maintaining a certain shape of at least a portion of the swellable material and / or contacting contact components of one or more movable arms. As shown in Figure 21A the swellable material is embedded in non-swelling features that encapsulate the swellable material in the state before administration (as shown in the subsequent Figure 21CAs shown, the non - inflatable feature 2128 expands with the inflatable material 2110 and contacts each movable arm). The body of the oral drug dosage form 2100 includes a lid 2112. The oral drug dosage form 2100 includes four movable arms( Figure 21A The view of shows three movable arms 2114, 2116, 2118), and at least a portion of each movable arm is extendable beyond the body of the oral drug dosage form 2100 or further by the force provided by the inflatable material 2110. Specifically, each movable arm is configured to rotate about an axis. For example, the first movable arm 2114 is configured to rotate about the first axis 2124. As Figure 21A shown in the pre - administration state, the oral drug dosage form 2100 may further include an erodible restraint 2122, which is configured to inhibit the extension of the movable arms in the pre - administration state. A cross - sectional view of the oral drug dosage form 2100 is as Figure 21B shown, where the inflatable material 2110 has expanded and exceeded (at least in part) the orifice 2106 of the body 2102, applying a force to each movable arm such that each movable arm moves to the extended position. Figure 21C The top - view shows the post - administration state of the oral drug dosage form 2100, where the first movable arm 2114, the second movable arm 2116, the third movable arm 2118, and the fourth movable arm 2120 are all shown in the extended position. In some embodiments, the post - administration state forms a design shape provided by the inflatable material and / or non - inflatable features. In some embodiments, the components of the oral drug dosage form 2100 can be produced, for example, by three - dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the pre - administration oral drug dosage form 2100. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of each movable arm, and these components are then assembled to form the oral drug dosage form.

[0109] An example of a dosage form 2200 having movable arms is provided in Figures 22A - 22B In Figure 22A the oral drug dosage form 2200 includes movable arms 2114, 2116. Specifically, each movable arm is configured to rotate about an axis. For example, the first movable arm 2114 is configured to rotate about the first axis 2224, and the second movable arm 2116 is configured to rotate about the second axis 2226, where the oral drug dosage form 2200 includes a body 2202 having an inflatable material chamber 2204, which is configured to contain at least a portion of the inflatable material 2210.

[0110] In Figure 22AIn the illustrated embodiment, the expandable material chamber 2204 contains an expandable material 2210 and a piston 2211, where the piston has a certain rigidity. In the pre - dosing state, the piston 2211 is located within the expandable material chamber 2204. In the post - dosing state, the expandable material 2210 absorbs a liquid (such as gastric juice or intestinal juice) and increases in volume, pushing the piston 2211 towards the movable arms 2114, 2116. The body 2202 includes an orifice 2206 operatively connected to the expandable material chamber 2204, where the swellable material swells in the presence of gastrointestinal fluid and the piston 2211 can extend beyond the orifice 2206. As Figure 22B shown, the pharmaceutical dosage form 2200 includes a body 2202, which includes a lid 2212 and a base 2201 therein, and the movable arms 2214, 2216 are pivotally connected to the lid 2212 by a pivot 2226, and one or more fluid inlets 2203 are operatively located in the base 2201. In some embodiments, the fluid inlets 2203 can be filled with a soluble substance. When the pharmaceutical dosage form comes into contact with water, the soluble substance begins to dissolve and the fluid inlets are connected to the expandable material chamber 2204. Each movable arm can rotate around the body, and the body of the oral pharmaceutical dosage form 2200 is driven by the force provided by the expandable material 2210. In some embodiments, the expandable material 2210 is pre - formed. After absorbing water, the expandable material 2210 expands in a preset shape until a portion of the expandable material 2210 extends out of the orifice 2206 and pushes the movable arm 2214 to rotate. The expandable material moves along the direction of the orifice until it is blocked by the lid 2212. A cross - sectional view of the oral pharmaceutical dosage form 2200 is shown in Figure 22B . In some embodiments, the components of the oral pharmaceutical dosage form 2200 can be produced, for example, by three - dimensional printing, injection molding, ultrasonic welding, or any combination thereof, and then assembled to form the oral pharmaceutical dosage form 2200 before dosing. For example, in some embodiments, the body (or one or more parts thereof) is produced independently of each movable arm, and these components are then assembled to form the oral pharmaceutical dosage form. B. Components and Materials of Oral Pharmaceutical Dosage Forms

[0111] In certain aspects, provided herein are components of an oral pharmaceutical dosage form, such as a swellable material and / or an expandable material and associated non - swelling features, including a swelling structure, one or more movable arms, a body and features formed therein, a drug, and an erodible restraint.

[0112] The pharmaceutical dosage forms described herein include one or more features that create a force that facilitates the change of the pre - administration state of the pharmaceutical dosage form to the post - administration state (in whole or in part). In some embodiments, an oral pharmaceutical dosage form includes a swellable material and / or an expandable material. The swellable materials described herein are configured to swell in the presence of gastrointestinal fluid and generate a force exerted on another movable arm, or a feature associated with the swellable material (e.g., a non - swellable feature covering at least a portion of the swellable material, including a non - swellable feature comprising a semi - permeable material), such that the oral pharmaceutical dosage form is transformed into an expanded post - administration form. In some embodiments, the oral pharmaceutical dosage form comprises a single unit of swellable material. In some embodiments, the oral pharmaceutical dosage form includes one or more swellable materials in two or more separate units (e.g., a first swellable material in a first swellable material chamber and a second swellable material in a second swellable material chamber). In embodiments having one or more swellable materials in more than two separate units, the swellable materials of these separate units can be the same or different.

[0113] In some embodiments, the swellable material and / or the expandable material are configured to swell at a desired rate and / or with a desired force. For example, in some embodiments, the swellable material and / or the expandable material are configured to swell rapidly upon contact with gastrointestinal fluid (including contact of the oral pharmaceutical dosage form with gastrointestinal fluid) to prevent the oral pharmaceutical dosage form from passing through the stomach prior to the gastric retention period required for gastric retention. In some embodiments, the swellable material and / or the expandable material are configured to swell with a force necessary to move the components of the oral pharmaceutical dosage form to a gastric retention state, such as moving one or more movable arms.

[0114] In some embodiments, after exposure to gastrointestinal fluid, the swellable material swells by at least about 1.2 times, such as at least about 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, or 2.0 times. In some embodiments, the swelling occurs within about 1 hour, such as within any of approximately 50 minutes, 40 minutes, 30 minutes, 20 minutes, 10 minutes, or 5 minutes. In some embodiments, the swellable material swells by at least about 1.2 times within 30 minutes, such as at least about 1.3 times, at least about 1.4 times, at least about 1.5 times, at least about 1.6 times, at least about 1.7 times, at least about 1.8 times, at least about 1.9 times, or at least about 2.0 times within 30 minutes after exposure to gastrointestinal fluid. In some embodiments, the swellable material reaches a substantially fully swollen state (e.g., absorbs at least about 90% of the fluid capacity) within about 1 hour or less, such as within approximately 50 minutes, 40 minutes, 30 minutes, 20 minutes, 10 minutes, or 5 minutes.

[0115] In some embodiments, when the swellable material swells, it at least partially conforms to the shape of the oriented channels and / or orifices or a portion thereof. In some embodiments, when the swellable material swells, it at least partially adopts a predetermined shape and / or size. In some embodiments, the predetermined shape and / or size is at least partially guided by non-swellable features associated with the swellable material, such as non-swellable material surrounding at least a portion of the swellable material in a pre-applied state. In some embodiments, the general shape of the swellable material after swelling is different from the shape of the swellable component before swelling. In some embodiments, the swellable material includes a coating. In some embodiments, the coating of the swellable material delays the swelling of the swellable material for at least a predetermined time after an oral pharmaceutical dosage form is administered to an individual, such as by inhibiting contact with gastrointestinal fluids and / or inhibiting swelling. In some embodiments, the coating completely surrounds the swellable material. In some embodiments, the coating partially surrounds the swellable material. In some embodiments, the swellable material is completely or partially surrounded by a semipermeable material.

[0116] In some embodiments, the swellable material includes sodium alginate (SA), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methylcellulose (HPMC), polyethylene oxide (PEO), polyvinyl alcohol (PVA), microcrystalline cellulose (MCC), croscarmellose sodium (CCNa), sodium carboxymethylcellulose (CMC-Na), polyvinylpolypyrrolidone (PVPP), sodium carboxymethyl starch (CMS-Na), polyethylene glycol (PEG), or a mixture thereof. In some embodiments, HPC includes L-HPC or H-HPC, or a combination thereof.

[0117] In some embodiments, the swellable material includes materials selected from the group consisting of crosslinked products and shape memory materials. In some embodiments, the swellable material includes materials selected from the group consisting of poly(ethylene oxide)-poly(ethylene glycol) (PEO-PEG) crosslinked polymers, poly(caprolactone)-poly(ethylene glycol)-poly(caprolactone) (PCL-PEG-PCL), hydroxypropyl cellulose, poly(ethylene oxide) (PEO), such as high molecular weight PEO, sodium alginate, carbomer, high molecular weight hydroxypropyl cellulose (HPC), high molecular weight hydroxypropyl methylcellulose or hypromellose (HPMC), methylcellulose (MC), high molecular weight poly(vinyl alcohol) (PVA), poly(vinyl acetate) (PVAc), and poly(vinylpyrrolidone) (PVP) 80 / 20, methacrylate copolymers, aminoalkyl methacrylate copolymers, aminoalkyl methacrylate copolymer E, hydroxypropyl methylcellulose succinate ester or hypromellose succinate ester (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), or combinations thereof. In some embodiments, the shape memory materials are selected from polyurethanes, block copolymers of polyethylene terephthalate (PET) and poly(ethylene oxide) (PEO), block copolymers containing polystyrene and poly(1,4-butadiene), ABA triblock copolymers made from poly(2-methyl-2-oxazoline) and polytetrahydrofuran, polynorbornene (Norsorex, developed by CdF Chemie / Nippon Zeon), polynorbornene with partially substituted polyhedral oligomeric silsesquioxane (POSS), made from polycyclooctene (PCOE) and poly(5-norbornene-exo,exo-2,3-dicarboxylic anhydride) (PNBEDCA), polyester-urethane, composites composed of polyols (soft segments) and diisocyanates combined with chain extenders (hard phase) (poly(ε-caprolactone) (PCL), polyethylene adipate (PEA) ethylene glycol), polyester-polyurethane (PUR) and PCL, ethylene oxide-ethylene terephthalate block copolymer combinations, PUR based on PUR(ε-caprolactone) and oligomeric (p-dioxanone), poly(p-dioxanone)-b-poly(tetramethylene glycol) multiblock copolymer, poly(methyl methacrylate)-poly(ethylene glycol) (PMMA-PEG) semi-interpenetrating network (IPN), poly(cyclohexyl methacrylate) (PCHMA) backbone crosslinked with a bifunctional PCL polymer, a polymer with short PEG side chains grafted onto the PCL backbone, copoly(ester-urethane) network, covalently crosslinked poly[ethylene-co-(vinyl acetate)] (cPEVA), combinations of PCL and poly(tetramethylene ether) glycol (PTMEG), or combinations thereof. In some embodiments, the material can have multiple properties, including swellable materials and shape memory materials.

[0118] In some embodiments, the swellable material further comprises a salt or a mixture of salts, e.g., to promote the absorption of gastrointestinal fluids to facilitate swelling. In some embodiments, the salt is selected from the group consisting of sodium salts, magnesium salts, and potassium salts. In some embodiments, the sodium salt is sodium sulfate.

[0119] In some embodiments, the swellable material further comprises a gas-generating substance, e.g., generating carbon dioxide upon contact with gastrointestinal fluids. In some embodiments, the gas-generating substance is selected from carbonates, bicarbonates, or combinations thereof.

[0120] In some embodiments, the expandable material comprises a group selected from the following materials: polyvinyl acetate (PVAc), povidone, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, ethylcellulose (EC), hydroxypropyl methylcellulose (HPMC), tocopheryl polyethylene glycol succinate (TPGS), polycaprolactone (PCL), polyethylene (PE), guar gum, polyetheretherketone (PEEK), polyphenylsulfone (PPSU), polysulfone (PSU), polypropylene (PP), ethylene vinyl acetate (EVA), polymethyl methacrylate (PMMA), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic) acid (PLGA), or combinations thereof.

[0121] In some embodiments, the swellable material does not contain a drug.

[0122] In some embodiments, the amount of the swellable material in the swellable material chamber is at least about 5 mg, e.g., any one of at least about 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, or 200 mg.

[0123] In some embodiments, the swellable material has a swelling volume of about 10 mm 3 to about 50 mm 3 In some embodiments, the swellable material has a swelling volume of at least about 5 mm 3 e.g., at least about 10 mm 3 15 mm 3 20 mm 3 25 mm 3 30 mm 3 35 mm 3 40 mm 3 45 mm 3 or 50 mm 3 any one of which.

[0124] In some embodiments, the swellable material can be printed by a three-dimensional printing process, injection molding, ultrasonic welding, or any combination thereof, as described in other aspects of the present disclosure. In some embodiments, the swellable material is a thermoformable material.

[0125] In some embodiments, the body comprises two or more components that are configured as the body. In some embodiments, the body comprises one or more bases and one or more lids. In some embodiments, the body comprises two or more materials. In some embodiments, the body of the oral pharmaceutical dosage form is a unitary structure. In some embodiments, the body delineates the outer boundary of the oral pharmaceutical dosage form in the pre-administration state. In some embodiments, the body can be printed by a three-dimensional printing process, injection molding, ultrasonic welding, or any combination thereof, as described in other aspects of the present disclosure. In some embodiments, the body is composed of a thermoformable material.

[0126] In some embodiments, the body comprises one or more swellable material chambers, such as any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 swellable material chambers. In some embodiments, the swellable material chamber is configured to substantially contain the oral pharmaceutical dosage form with the swellable material in the pre-administration state. In some embodiments, the contact assembly of the swellable material chamber and the movable arm substantially surrounds the swellable material in the pre-administration state of the oral pharmaceutical dosage form. The swellable material chamber can be of any size and / or shape.

[0127] In some embodiments, the body comprises one or more guiding channels and / or orifices. In some embodiments, the guiding channels are configured to guide the movement of the movable arm by the force provided by the swellable material. The guiding channels and / or orifices can be of any shape and / or size, and, as described herein, such shape and / or size can be guided by other design features of the oral pharmaceutical dosage form, for example, the mechanism and shape of the movable arm and the amount of swellable material required to obtain the post-gastric retention administration state. In some embodiments, the guiding channels comprise channels with a curved shape. In some embodiments, the guiding channels comprise circular channels. In some embodiments, the guiding channels comprise square or rectangular channels. In some embodiments, the orifice is square or circular or rectangular.

[0128] In some embodiments, the guiding channels further comprise one or more fluid inlets (described below) that are configured to further expose the swellable material to gastrointestinal fluid during the swelling process.

[0129] In some embodiments, the body includes one or more fluid inlets, such as from about 5 to about 20, for each swellable material chamber, wherein one or more fluid inlets are operatively connected to the swellable material chamber. In some embodiments, at least one of the one or more fluid inlets comprises a semipermeable material. In some embodiments, at least one of the one or more fluid inlets is a semipermeable material that fills the pores formed by the body. In some embodiments, one or more fluid inlets are semipermeable membranes that at least partially wrap around the swellable material. In some embodiments, at least one of the one or more fluid inlets is a pore. In some embodiments, one or more fluid inlets are holes having a maximum cross-sectional dimension (e.g., diameter) of from about 0.5 to about 1 mm. The holes can be any shape, including circular, square, or rectangular.

[0130] In some embodiments, the body further forms a stop configured to engage the movable arm in an extended position. The stop can be any part of the body and does not require a specific design. In some embodiments, the stop includes a locking assembly configured to hold the movable arm in one or more extended positions.

[0131] As described herein, an oral dosage form includes one or more movable arms, such as any one of 1, 2, 3, 4, 5, 6, 7, 8, or 10. The movable arms can be designed using several mechanisms based on the swelling of a swellable material, and the oral dosage form can implement one or more such mechanisms. In some embodiments, the movable arm or a portion thereof is configured to slide within a guiding channel. In some embodiments, the contact assembly of the movable arm is configured to slide within a guiding channel. In some embodiments, the movable arm is configured to rotate about an axis. In some embodiments, at least two movable arms or the oral dosage form have different movement mechanisms. In some embodiments, at least two movable arms of the oral dosage form have the same movement mechanism. In some embodiments, at least two movable arms of the oral dosage form are configured such that at least a portion of each movable arm can be extended beyond or further from the body of the oral dosage form by a force provided by the swellable material, and one or more movable arms are associated with a single swellable material in the swellable material chamber. For example, the swellable material in the swellable material chamber swells and causes the driving of one or more movable arms. In some embodiments, the oral dosage form includes two movable arms, wherein the first movable arm is associated with a first swellable material in a first swellable material chamber and the first movable arm is associated with a second swellable material in a second swellable material chamber.

[0132] In some embodiments, the oral pharmaceutical dosage form further includes an erodible restraint configured to inhibit the extension of one or more movable arms over a period of time. Generally, the erodible restraint is configured to facilitate oral administration of the oral pharmaceutical dosage form, e.g., by preventing premature extension of one or more movable arms before entering the stomach of an individual. In some embodiments, the erodible restraint is eroded within about 30 minutes after administration to an individual, e.g., within any one of about 25 minutes, 20 minutes, 15 minutes, 10 minutes, or 5 minutes.

[0133] In some embodiments, certain components of the oral pharmaceutical dosage form, such as the body or the movable arms, include insoluble materials; pH-sensitive erodible materials, e.g., materials that are insoluble at the pH of the stomach; slowly erodible materials, e.g., materials or components thereof that erode after the oral pharmaceutical dosage form leaves the stomach; or combinations thereof. In some embodiments, certain components, such as the body or the movable arms, include materials selected from the group consisting of ammonium methacrylate copolymer, type B ammonium methacrylate copolymer, stearic acid, ethyl cellulose (EC), titanium dioxide, cellulose acetate phthalate (CAP), poly(lactide-co-glycolide) (PLGA), ethylene-vinyl acetate copolymer, polyethylene (PE), polycaprolactone (PCL), polylactic acid (PLA), cellulose acetate butyrate (CAB), cellulose acetate (CA), polyvinyl acetate (PVAc), poly(vinyl acetal diethylamino lactate) (AEA), poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate), and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) or combinations thereof.

[0134] In some embodiments, the material of components of the pharmaceutical dosage form, such as the body or the movable arms, is a thermoplastic material. In some embodiments, the thermoplastic material is a thermoplastic polymer. In some embodiments, the thermoplastic material includes any one or more of a plasticizer and another additive, e.g., a filler, a binder, a lubricant, a glidant, and a disintegrant. In some embodiments, the additive is selected from clay, SiC nanoparticles, Ni powder, carbon nanotubes, carbon fibers, carbon black, graphene, metal oxides (e.g., Fe 3 O 4 、TiO 2 、ZnO), silver (Ag) nanoparticles, gold (Au) nanoparticles, silver and gold nanoparticles, nanorods, nanowhiskers, nanowires, and cellulose nanocrystals.

[0135] In some embodiments, the body is configured to have a wall thickness of at least about 0.3 mm (e.g., from the swellable material chamber to the outer portion of the oral dosage form or from the directional channel to the outer portion of the oral dosage form) of at least about 0.3 mm, such as at least about 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.0 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.1 mm, 2.2 mm, 2.3 mm, 2.4 mm, or 2.5 mm. In some embodiments, the body is configured to have a wall thickness of from about 0.3 mm to about 2.5 mm (e.g., from the swellable material chamber to the outer portion of the oral dosage form or from the directional channel to the outer portion of the oral dosage form) of from about 0.3 mm to about 2.5 mm, such as any of from about 0.5 mm to about 2.2 mm or from about 0.4 mm to about 1.2 mm.

[0136] In some embodiments, the arm is configured to have a thickness of from about 1 mm to about 2 mm, such as from about 1.1 mm to about 1.6 mm.

[0137] In some embodiments, the oral dosage form includes a component that is a plunger or piston, such as a plunger, configured to be pushed by the swellable material into one or more arms. In some embodiments, the column includes a wall thickness of from about 0.3 mm to about 2.5 mm, such as from about 0.4 mm to about 2.2 mm. In some embodiments, the column includes a wall thickness of at least about 0.3 mm, such as at least about 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.0 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.1 mm, 2.2 mm, 2.3 mm, 2.4 mm, or 2.5 mm. C. Incorporating one or more drugs and drug release profiles in an oral dosage form

[0138] The oral pharmaceutical dosage forms described herein include one or more drugs. In some embodiments, the oral pharmaceutical dosage form includes a drug that comprises a separate portion of the pharmaceutical formulation and is configured with a substantially matching or different release profile. In some embodiments, the oral pharmaceutical dosage form includes two or more drugs, such as any one of 3, 4, or 5 drugs. The drugs of the oral pharmaceutical dosage form can be released at any point in the life cycle of the oral pharmaceutical dosage form. For example, in some embodiments, the oral pharmaceutical dosage form is configured and formulated to release the drug in the stomach of an individual. In some embodiments, substantially all, such as at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% of any one of the oral pharmaceutical dosage forms is released in the stomach. In some embodiments, the oral pharmaceutical dosage form is configured to release the drug before or during the swelling of a swellable material, such as an immediate release profile. In some embodiments, the pharmaceutical dosage form is configured to release the drug after leaving the stomach.

[0139] In some embodiments, the drug is a poorly water-soluble drug. In some embodiments, the poorly water-soluble drug is a Biopharmaceutics Classification System (BCS) class II active pharmaceutical ingredient (API), such as a drug with high permeability and low solubility. In some embodiments, the poorly water-soluble drug is a Biopharmaceutics Classification System (BCS) class IV active pharmaceutical ingredient (API), such as a drug with low permeability and low solubility. In some embodiments, the drug is a Biopharmaceutics Classification System (BCS) class III active pharmaceutical ingredient (API), such as a drug with low permeability and high solubility. In some embodiments, the drug is selected from riociguat, aceclofenac, bicalutamide, carbamazepine, carvedilol, clotrimazole, cinnarizine, danazol, dapsone, estradiol, etimicin, glibenclamide, fenofibrate, griseofulvin, ibuprofen, itraconazole, ketoconazole, mefenamic acid, naproxen, nevirapine, nifedipine, nitrofurantoin, nomegestrol acetate, phenytoin sodium salt, piroxicam, praziquantel, rifampicin, sulfamethoxazole, trimethoprim, and verapamil hydrochloride.

[0140] Oral pharmaceutical dosage forms can be configured to release a drug based on any desired release profile and be formulated to release more than one drug, where each drug has any desired release profile. Generally, since the oral pharmaceutical dosage forms described herein are designed to remain in the stomach for an extended period of time, the release profile of at least one drug will be configured based on the expected gastric retention of the oral pharmaceutical dosage form. In some embodiments, when two or more drugs are in an oral pharmaceutical dosage form, the oral pharmaceutical dosage form is configured to release each drug according to a desired release profile. In some embodiments, the oral pharmaceutical dosage form is configured such that all of the drug content (or substantially all, e.g., at least about 90%) in the oral pharmaceutical dosage form (or a portion thereof) is released during the expected gastric retention of the oral pharmaceutical dosage form. In some embodiments, the oral pharmaceutical dosage form is configured to release a certain amount of the drug content (e.g., a second drug) in the oral pharmaceutical dosage form after the oral pharmaceutical dosage form or its components are expected to be emptied from the stomach. In some embodiments, the oral pharmaceutical dosage form is formulated and configured such that the drug is released according to a delayed release profile, a sustained release profile, a delayed-sustained release profile, a zero-order release profile, a first-order release profile, an immediate release profile plus a sustained release profile, an immediate release profile plus a delayed release profile, an immediate release profile plus a delayed-sustained release profile, a pulsed release profile, an iterative pulsed release profile, an immediate release profile plus a pulsed release profile, or a combination thereof.

[0141] The oral pharmaceutical dosage forms described herein can be configured and formulated to release a drug according to a desired drug release profile using a variety of techniques. In some embodiments, the drug is released from the oral pharmaceutical dosage form based on the erosion of the drug-containing material, such as when the drug-containing material is exposed to gastrointestinal fluids. In some specific embodiments, the drug-containing material is configured as a layer having a predetermined surface area that is exposed to gastrointestinal fluids, a thickness, and a drug mass fraction, where these properties of the drug-containing material provide the desired drug release. In some embodiments, the drug-containing material is in the form of a multi-layer structure. In some embodiments, the drug-containing material is encapsulated, including being partially encapsulated in a material of a component of the pharmaceutical dosage form. The design, configuration, and materials of such drug-containing materials to provide the desired drug release are known in the art; for example, see U.S. Patent No. 10,350,822, which is incorporated herein by reference in its entirety.

[0142] In some embodiments, an oral pharmaceutical dosage form is configured with a drug-containing chamber having an orifice for releasing the drug from the oral pharmaceutical dosage form. In some embodiments, the orifice is plugged with an erodible material (e.g., a plug). In some embodiments, the feature plugging the orifice, such that the drug remains within the chamber of the oral pharmaceutical dosage form, is configured to no longer plug the orifice at a desired time. For example, in some embodiments, the drug-containing chamber is sealed with an erodible plug, where the erodible plug dissolves at a certain time after administration to an individual, thereby releasing the drug from the oral pharmaceutical dosage form. The release time can be based on, for example, the thickness of the plug and / or the material of the plug. The drug-containing chamber can be configured in any component. In some embodiments, the oral pharmaceutical dosage form includes a plurality of drug-containing chambers. In some embodiments, the component is a non-erodible material, such as an insoluble shell material. In some embodiments, the component is eroded after the drug leaves the drug-containing chamber, e.g., after the oral pharmaceutical dosage form leaves the stomach.

[0143] In some embodiments, the oral pharmaceutical dosage form is configured such that the drug will leach or diffuse from the material.

[0144] In some embodiments, the drug is loaded on one or more movable arms; in some embodiments, each movable arm is loaded with the drug. In some embodiments, the drug is loaded on one or more caps. In some embodiments, the drug is loaded in a swellable material chamber.

[0145] The drug of the pharmaceutical dosage forms described herein can be part of any of the components described herein. In some embodiments, the drug is not located in the swellable material. In some embodiments, the swellable material does not include the drug. D. The oral pharmaceutical dosage form provides the feature of gastric retention in the post-administration state

[0146] As described herein, the swelling of one or more swellable materials or portions thereof increases the size of the oral pharmaceutical dosage form, thereby allowing the drug to remain in the stomach for a longer period of time. In some embodiments, the post-administration state of the oral pharmaceutical dosage form is referred to as the gastric retention state. Those of ordinary skill in the art will readily understand that the features of the oral pharmaceutical dosage form, such as size, can be dynamic and change over time during the swelling of the swellable material or a portion thereof. The description of certain states of the oral pharmaceutical dosage form, such as the post-administration gastric retention state, is not intended to limit the disclosure herein to a single static embodiment of the pharmaceutical dosage form.

[0147] In some embodiments, when the oral pharmaceutical dosage form is in an expanded state (e.g., a gastric retention state), the size of the oral pharmaceutical dosage form is such that it inhibits and / or prevents the oral pharmaceutical dosage form from reaching the duodenum through a particular aspect of the pylorus (e.g., the pyloric orifice created by the pyloric antrum, pyloric canal, or pyloric sphincter). In some embodiments, when the oral pharmaceutical dosage form is in an expanded state, the size of the oral pharmaceutical dosage form is such that it inhibits and / or prevents the oral pharmaceutical dosage form from passing through the pyloric orifice created by the pyloric sphincter. In some embodiments, when the oral pharmaceutical dosage form is in an expanded state, at least two perpendicular dimensions of the oral pharmaceutical dosage form each independently have a length of at least about 20 mm to about 70 mm, such as a length of at least about 20 mm to about 50 mm, about 30 mm to about 60 mm, or a length of about 40 mm to about 70 mm. In some embodiments, when the pharmaceutical dosage form is in an expanded state, at least two perpendicular dimensions of the pharmaceutical dosage form each independently are at least about 20 mm, such as at least about 25 mm, 30 mm, 35 mm, 40 mm, 45 mm, 50 mm, 55 mm, 60 mm, 65 mm, or 70 mm in length. In some embodiments, when the oral pharmaceutical dosage form is in an expanded state, at least two perpendicular dimensions of the pharmaceutical dosage form each independently are about any one of 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, 45 mm, 50 mm, 55 mm, 60 mm, 65 mm, or 70 mm in length. In some embodiments, when the oral pharmaceutical dosage form is in an expanded state, one dimension of at least two perpendicular dimensions is different from the other dimension. In some embodiments, when the pharmaceutical dosage form is in an expanded state, one dimension of at least two perpendicular dimensions is the same as the other dimension. It should be noted that individuals may have different anatomical characteristics and sizes (e.g., adults vs. children), and the present application includes oral pharmaceutical dosage forms designed to account for these considerations to achieve the desired gastric retention.

[0148] The oral pharmaceutical dosage forms described herein are configured to remain in the stomach for a longer period of time, e.g., compared to pharmaceutical dosage forms that do not have a gastric retention feature (e.g., the oral pharmaceutical dosage form naturally follows the flow of ingested material through the stomach). In some embodiments, the oral pharmaceutical dosage form is configured to remain in the stomach for from about 8 hours to about 3 months, such as from about 8 hours to about 24 hours, from about 8 hours to about 36 hours, from about 18 hours to about 30 hours, from about 20 hours to about 28 hours, from about 12 hours to about 36 hours, from about 1 day to about 3 days, from about 3 days to about 7 days, from about 8 hours to about 1 month, or from about 8 hours to about 2 months. In some embodiments, the oral pharmaceutical dosage form is configured to remain in the stomach for at least about 8 hours, such as at least about 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, or 36 hours. In some embodiments, the oral pharmaceutical dosage form is configured to remain in the stomach for at least about 1 day, such as at least about 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 21 days, 1 month, 1.5 months, 2 months, 2.5 months, or 3 months. In some embodiments, the oral pharmaceutical dosage form is configured to remain in the stomach for no more than about 7 days, such as no more than about 6 days, 5 days, 4 days, 3 days, 2 days, 36 hours, 30 hours, 24 hours, 18 hours, or 12 hours. In some embodiments, the oral pharmaceutical dosage form is configured to remain in the stomach for no more than about 3 months, such as no more than about 2.5 months, 2 months, 1.5 months, 1 month, 21 days, 14 days, or 7 days. In some embodiments, the oral pharmaceutical dosage form is configured to remain in the stomach for about 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 21 days, 1 month, 1.5 months, 2 months, 2.5 months, or 3 months.

[0149] In some embodiments, the post - administration state of the oral pharmaceutical dosage form occurs within about 1 hour or less after the oral pharmaceutical dosage form is administered to an individual. For example, in some embodiments, the oral pharmaceutical dosage form achieves a gastric retention state within about 1 hour or less, 50 minutes or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 10 minutes or less, or 5 minutes or less after administration to the individual.

[0150] In some embodiments, the oral pharmaceutical dosage form is configured such that the oral pharmaceutical dosage form or a portion thereof is capable of passing through the pylorus and exiting the stomach. For example, in some embodiments, one or more components of the oral pharmaceutical dosage form, such as one or more movable arms, erode and / or soften in the stomach, thereby allowing for exit from the stomach in one or more portions. In some embodiments, the oral pharmaceutical dosage form softens after a period of gastric retention and is configured to pass through the pylorus as a whole. In some embodiments, the erosion or dissolution of a component or a portion thereof of the oral pharmaceutical dosage form is due to prolonged exposure to gastrointestinal fluids in the stomach (e.g., due to prolonged exposure to a low pH). E. Characteristics of the Oral Pharmaceutical Dosage Form in the Pre - administration State

[0151] The oral pharmaceutical dosage forms described herein can assume any number of shapes, sizes, weights, and appearances. As described herein, the oral pharmaceutical dosage forms of the present application can take forms with different characteristics (such as size and shape) during the life cycle of the administered oral pharmaceutical dosage form (e.g., the administration state and the post - administration gastric retention state).

[0152] In some embodiments, the oral pharmaceutical dosage forms described herein are suitable for oral administration to a human individual. Such oral pharmaceutical dosage forms of the present application can be, for example, of any size, shape, or weight suitable for oral administration to a specific human individual, such as a child and an adult. In some embodiments, the oral pharmaceutical dosage form is suitable for oral administration to an individual, wherein the size, shape, or weight of the pharmaceutical dosage form is selected based on the attributes of the individual, such as one or more of height, weight, age, or anatomical characteristics, such as those related to oral administration.

[0153] In some embodiments, the surface of the oral pharmaceutical dosage form, such as the outer surface, such as the body, has a capsule shape, circular, oval, bullet - shaped, arrow - shaped, triangular, arc - triangular, square, arc - square, rectangular, arc - rectangular, rhombus, pentagon, hexagon, octagon, semi - circular, almond - shaped, or a combination thereof.

[0154] In some embodiments, the maximum cross-sectional dimension of the oral pharmaceutical dosage form is from about 5 mm to about 26 mm, such as from about 5 mm to about 15 mm, from about 6 mm to about 13 mm, or from about 7 to about 11 mm. In some embodiments, the maximum cross-sectional dimension of the oral pharmaceutical dosage form is at least about 5 mm, such as at least about 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, or 24 mm. In some embodiments, the maximum cross-sectional dimension of the pharmaceutical dosage form is less than about 26 mm, such as less than about 25 mm, 24 mm, 23 mm, 22 mm, 21 mm, 20 mm, 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the maximum cross-sectional dimension of the pharmaceutical dosage form is about 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 20.5 mm, 21 mm, 21.5 mm, 22 mm, 22.5 mm, 23 mm, 23.5 mm, or 24 mm. In some embodiments, the maximum cross-sectional dimension is measured on the surface of the pharmaceutical dosage form, such as the outer surface (e.g., represented by the length or width of the oral pharmaceutical dosage form). In some embodiments, the measured maximum cross-sectional dimension passes through or along a diagonal through the oral pharmaceutical dosage form.

[0155] In some embodiments, the oral pharmaceutical dosage form has a cross dimension perpendicular to the maximum cross dimension of from about 5 mm to about 20 mm, such as any one of from about 5 mm to about 15 mm, from about 6 mm to about 13 mm, or from about 7 to about 11 mm. In some embodiments, the oral pharmaceutical dosage form has a cross dimension perpendicular to the maximum cross dimension of at least about 5 mm, such as at least about 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the oral pharmaceutical dosage form has a cross dimension perpendicular to the maximum cross dimension that is less than about 20 mm, such as less than about 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the oral pharmaceutical dosage form has a cross dimension perpendicular to the maximum cross dimension that is approximately any one of 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the cross dimension perpendicular to the maximum cross dimension is measured on the surface of the oral pharmaceutical dosage form. In some embodiments, the cross dimension perpendicular to the maximum cross dimension is measured through or along a diagonal through the oral pharmaceutical dosage form.

[0156] In some embodiments, the thickness of the oral pharmaceutical dosage form is from about 5 mm to about 20 mm, such as any one of from about 5 mm to about 15 mm, from about 6 mm to about 13 mm, or from about 7 to about 11 mm. In some embodiments, the oral pharmaceutical dosage form has a thickness of at least about 5 mm, such as at least about 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm. In some embodiments, the thickness of the oral pharmaceutical dosage form is less than about 20 mm, such as any one of less than about 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm, 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, or 5 mm. In some embodiments, the thickness of the oral pharmaceutical dosage form is approximately any one of 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, or 20 mm.

[0157] In some embodiments, the total weight of the oral pharmaceutical dosage form is from about 50 mg to about 1,000 mg, such as from about 50 mg to about 100 mg, from about 100 to about 200 mg, from about 200 mg to about 300 mg, from about 300 mg to about 400 mg, from about 400 mg to about 500 mg, from about 500 mg to about 600 mg, from about 600 mg to about 700 mg, from about 700 mg to about 800 mg, from about 800 mg to about 900 mg, or from about 900 mg to about 1,000 mg. In some embodiments, the total weight of the oral pharmaceutical dosage form is at least about 50 mg, such as at least about 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg or 1,000 mg. In some embodiments, the total weight of the oral pharmaceutical dosage form is less than about 1,000 mg, such as less than about 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 475 mg, 450 mg, 425 mg, 400 mg, 375 mg, 350 mg, 325 mg, 300 mg, 275 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg, 75 mg or 50 mg. In some embodiments, the total weight of the oral pharmaceutical dosage form is about 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg or 1,000 mg. F. Additional Features of the Pharmaceutical Dosage Form

[0158] In some embodiments, the oral pharmaceutical dosage form includes an inflatable chamber, for example, to provide buoyancy to the oral pharmaceutical dosage form. In some embodiments, the inflatable chamber is embedded in a component of the oral pharmaceutical dosage form, such as the body or one or more movable arms. In some embodiments, the inflatable chamber has an erodible plug, wherein the erodible plug is configured to open the inflatable chamber at some point after the oral pharmaceutical dosage form is administered to an individual.

[0159] In some embodiments, the oral pharmaceutical dosage form includes additional features such as an outer coating, an outer layer (e.g., a capsule shell), or an external marking. In some embodiments, the outer coating or outer layer comprises / is a flavor coating. In some embodiments, the outer coating or outer layer comprises / is a sugar coating. In some embodiments, the outer coating or outer layer comprises / is a cosmetic coating. In some embodiments, the outer coating or outer layer comprises / is a colored coating. In some embodiments, the outer coating or outer layer is a film coating. In some embodiments, the outer coating or outer layer is a polymer coating. In some embodiments, the outer coating completely surrounds the pharmaceutical dosage form. In some embodiments, the outer layer forms a part of the exterior of the oral pharmaceutical dosage form. In some embodiments, the additional component is a label, such as a drug identification, a company name or abbreviation, a graphic, a drug label, a drug chemical name or abbreviation, a drug instruction manual, an identification barcode, or a combination thereof. G. Exemplary Medical Devices

[0160] The above inventive concept can be applied to medical devices. In some embodiments, a medical device for gastric retention is provided, the medical device comprising: an expandable material; a movable arm configured such that at least a portion of the movable arm can be extended or retracted from the oral pharmaceutical dosage form by a force provided by the expandable material; the body comprising: an expandable material chamber configured to contain at least a portion of the expandable material; a directional channel operatively connected to the expandable material chamber, wherein the movable arm includes a contact assembly configured to be adjacent to the directional channel of the expandable material, wherein the expandable material chamber and the contact assembly of the movable arm substantially surround the expandable material, and wherein the movable arm or a portion thereof is configured to slide within the directional channel such that the movable arm extends along an axis based on the directional channel, beyond or rotates around the medical device body; one or more fluid inlets, such as orifices or semi-permeable materials, operatively connected to the deployable material chamber; and a drug, wherein the medical device is configured to have a compact form in the pre-administration state and a deployed form that provides gastric retention, wherein the deployed form of the medical device in the post-administration state is due, at least in part, to the expansion of a substance in the presence of gastrointestinal fluid. In some embodiments, the body includes a matrix and a lid. In some embodiments, the expandable material includes a plunger. H. Exemplary Oral Pharmaceutical Dosage Forms

[0161] In some embodiments, there is provided an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral dosage form by a force provided by the swellable material; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel operatively connected to the swellable material chamber, wherein the movable arm includes a contact assembly configured to contact the swellable material proximate the orienting channel, wherein the swellable material chamber and the contact assembly of the movable arm substantially surround the swellable material, and wherein the movable arm or a portion thereof is configured to slide within the orienting channel such that the movable arm extends out or further from the body of the oral dosage form along an axis based on the orienting channel; one or more fluid inlets, such as a semipermeable material, operatively connected to the swellable material chamber; one or more stops configured to engage the movable arm in an extended position; and a drug, wherein the oral dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form providing gastric retention, and wherein the expanded form of the post - dosing state of the oral dosage form is due at least in part to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the stop includes a locking assembly configured to hold the movable arm in one or more extended positions. In some embodiments, the locking assembly is configured to hold the movable arm in a single position. In some embodiments, the locking assembly is configured to hold the movable arm in a plurality of advanced positions.

[0162] In some embodiments, there is provided an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended beyond or further from the body of the oral dosage form by a force provided by the swellable material, wherein the first movable arm and the second movable arm extend in generally opposite directions along an axis based on a directional channel; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a first directional channel and a second directional channel operatively connected to the swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the swellable material near the second directional channel, wherein the swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm generally surround the swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel such that the first movable arm extends along the axis out of or further from the body of the oral dosage form, wherein the second movable arm or a portion thereof is configured to slide within the second directional channel such that the second movable arm extends along the axis out of or further from the body of the oral dosage form; one or more fluid inlets operatively connected to the swellable material chamber; a first stop configured to engage the first movable arm in an extended position; a second stop configured to engage the second movable arm in an extended position; and a drug, wherein the oral dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral dosage form is due to, at least in part, the swelling of the swellable material in the presence of gastrointestinal fluid.

[0163] In some embodiments, an oral dosage form for gastric retention is provided, the oral dosage form comprising: a first swellable material; a first movable arm, wherein the first movable arm is configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral dosage form by a force provided by the first swellable material, and wherein the first movable arm is configured to rotate about a first axis; a second swellable material; a second movable arm, wherein the second movable arm is configured such that at least a portion of the movable arm is extendable beyond or further from the body of the oral dosage form by a force provided by the second swellable material, and wherein the second movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel operably connected to the first swellable material chamber, wherein the first directional channel comprises a curved channel, wherein the first movable arm comprises a first contact assembly configured to contact the first swellable material in proximity to the first directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm substantially surround the first swellable material, wherein the first movable arm or a portion thereof is configured to rotate about the first axis by the first contact assembly sliding in the first directional channel such that the first movable arm extends out or further from the body of the oral dosage form, one or more fluid inlets operably connected to the first swellable material chamber; a second swellable material chamber configured to contain at least a portion of the second swellable material; a second directional channel operably connected to the second swellable material chamber, wherein the second directional channel comprises a channel having a curved shape, wherein the second movable arm comprises a second contact assembly configured to contact the second swellable material when in proximity to the second directional channel, wherein the second swellable material chamber and the second contact assembly of the second movable arm substantially surround the second swellable material, wherein the second movable arm or a portion thereof is configured to rotate about the second axis by the second contact assembly sliding in the second directional channel such that the second movable arm extends out or further from the body of the oral dosage form, one or more fluid inlets operably connected to the second swellable material chamber; a drug, wherein the oral dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in a deployed form providing gastric retention, and wherein the deployed form of the post - dosing state of the oral dosage form is due to, at least in part, the swelling of the swellable material in the presence of gastrointestinal fluid.

[0164] In some embodiments, an oral pharmaceutical dosage form for gastric retention is provided, the oral pharmaceutical dosage form comprising: a first swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended outside or further from the body of the oral pharmaceutical dosage form by the force provided by the first swellable material, wherein the first movable arm and the second movable arm extend in substantially opposite directions along an axis based on a directional channel; a second swellable material; a third movable arm, wherein the third movable arm is configured such that at least a portion of the third movable arm can be extended outside or further from the body of the oral pharmaceutical dosage form by the force provided by the second swellable material, and wherein the third movable arm is configured to rotate about a first axis; a third swellable material; a fourth movable arm, wherein the fourth movable arm is configured such that at least a portion of the fourth movable arm can be extended outside or further from the body of the oral pharmaceutical dosage form by the force provided by the third swellable material, and wherein the fourth movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel and a second directional channel operatively connected to the first swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the first swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the first swellable material near the second directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm substantially surround the first swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel such that the first movable arm extends along the axis out of or further from the body of the oral pharmaceutical dosage form, wherein the second movable arm or a portion thereof is configured to slide within the second directional channel such that the second movable arm extends along the axis out of or further from the body of the oral pharmaceutical dosage form; one or more fluid inlets operatively connected to the first swellable material chamber; a first stop configured to engage the first movable arm in an extended position; a second stop configured to engage the second movable arm in an extended position; a second swellable material chamber configured to contain at least a portion of the second swellable material;A third directional channel operably connected to the second swellable material chamber, wherein the third directional channel includes a curved channel, wherein the third movable arm includes a contact assembly configured to contact the second swellable material near the third directional channel, wherein the second swellable material chamber and the contact assembly of the third movable arm substantially surround the second swellable material, wherein the third movable arm or a portion thereof is configured to rotate about a first axis by sliding the contact assembly along the third directional channel, such that the third movable arm extends out from or further away from the body of the oral drug dosage form, one or more fluid inlets operably connected to the third swellable material chamber; a third swellable material chamber configured to contain at least a portion of the third swellable material; a fourth directional channel operably connected to the third swellable material chamber, wherein the fourth directional channel includes a channel having a curved shape, wherein the fourth movable arm includes a contact assembly configured to contact the third swellable material near the fourth directional channel, wherein the third swellable material chamber and the contact assembly of the fourth movable arm substantially surround the third swellable material, wherein the fourth movable arm or a portion thereof is configured to rotate about a second axis by sliding the contact assembly along the fourth directional channel, such that the fourth movable arm extends out from or further away from the body of the oral drug dosage form, one or more fluid inlets operably connected to the third swellable material chamber; and a drug, wherein the oral drug dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form providing gastric retention, and wherein the expanded form of the post - dosing state of the oral drug dosage form is at least partially due to the swelling of the first swellable material, the second swellable material, and the third swellable material in the presence of gastrointestinal fluid.;

[0165] In some embodiments, there is provided an oral dosage form for gastric retention, the oral dosage form comprising: a swellable material; a first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended beyond or further from the body of the oral dosage form by a force provided by the swellable material, wherein the first movable arm and the second movable arm are configured to rotate in opposite directions about a shared axis; the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; a first guiding channel and a second guiding channel operatively connected to the swellable material chamber, wherein the first guiding channel and the second guiding channel are curved and configured about the shared axis, wherein the first movable arm includes a first contact assembly configured to contact the swellable material adjacent to the first guiding channel, wherein the first contact assembly is in the shape of a rudder and is configured to travel in the first guiding channel such that the first movable arm rotates relative to the shared axis beyond or further from the body of the oral dosage form, wherein the second movable arm includes a second contact assembly configured to contact the swellable material adjacent to the second guiding channel, wherein the second contact assembly is in the shape of a rudder and is configured to travel in the second guiding channel such that the second movable arm rotates relative to the shared axis beyond or further from the body of the oral dosage form, one or more fluid inlets operatively connected to the swellable material chamber; one or more stoppers configured to engage the first movable arm and the second movable arm in an extended position; a drug, wherein the oral dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form providing gastric retention, and wherein the expanded form of the post - dosing state of the oral dosage form is due to, at least in part, the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the stopper or the one or more stoppers are configured to engage the first contact assembly of the first movable arm and the second contact assembly of the second movable arm in an extended position.

[0166] In some embodiments, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction towards a vertical plane of position along an independent axis by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or orifice operably connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material near the orienting channel and / or orifice, and wherein the swellable material chamber, the contact assemblies of the movable arms, and a lid substantially surround the swellable material; one or more fluid inlets operably connected to the swellable material chamber; a lid; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre-administration state in a compact form and a post-administration state in an expanded form providing gastric retention, and wherein the expanded form of the post-administration state of the oral pharmaceutical dosage form is due to, at least in part, the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the oral pharmaceutical dosage form further comprises a fifth movable arm. In some embodiments, the oral pharmaceutical dosage form further comprises a sixth movable arm. In some embodiments, the oral pharmaceutical dosage form further comprises an erodible restraint configured to inhibit the extension of the movable arms. In some embodiments, the swellable material is configured with a related non-swellable material covering at least a portion of the swellable material, and in such embodiments, the related non-swellable material may contact the movable arms.

[0167] In some embodiments, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction toward a vertical plane of position along an independent axis by a force provided by the swellable material, the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; an orienting channel and / or orifice operably connected to the swellable material chamber, wherein each movable arm includes a contact assembly configured to contact the swellable material proximate the orienting channel and / or orifice, and wherein the swellable material chamber and the contact assemblies of the movable arms substantially surround the swellable material; one or more fluid inlets operably connected to the swellable material chamber; a first stop, a second stop, a third stop, and a fourth stop respectively configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form providing gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is due, at least in part, to the swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the oral pharmaceutical dosage form further comprises a fifth movable arm. In some embodiments, the oral pharmaceutical dosage form further comprises a sixth movable arm. In some embodiments, the oral pharmaceutical dosage form further comprises an erodible restraint configured to inhibit the extension of the movable arms. In some embodiments, the swellable material is configured with a related non - swellable material covering at least a portion of the swellable material, and in such embodiments, the related non - swellable material may contact the movable arms.

[0168] In some embodiments, there is provided an oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material, wherein the swellable material is at least partially encapsulated by a semipermeable membrane; a first movable arm, a second movable arm, a third movable arm, and a fourth movable arm, wherein the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm are configured such that each arm rotates in a direction towards a vertical plane of position along an independent axis by a force provided by the swellable material; and comprising: a first connection point of the first arm, a second connection point of the second arm, a third connection point of the third arm, a fourth connection point of the fourth arm, wherein each connection point is configured to provide an independent axis for rotation of the first arm, the second arm, the third arm, and the fourth arm, wherein each movable arm includes a contact assembly configured to contact the swellable material or the semipermeable material, and a first stop, a second stop, a third stop, and a fourth stop, the stops being configured to engage the first movable arm, the second movable arm, the third movable arm, and the fourth movable arm, respectively, in an extended position, wherein the oral pharmaceutical dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form providing gastric retention, and wherein the expanded form of the post - dosing state of the oral pharmaceutical dosage form is due, at least in part, to swelling of the swellable material in the presence of gastrointestinal fluid. In some embodiments, the oral pharmaceutical dosage form further comprises a fifth movable arm. In some embodiments, the oral pharmaceutical dosage form further comprises a sixth movable arm. In some embodiments, the oral pharmaceutical dosage form further comprises an erodible restraint configured to inhibit extension of the movable arms. In some embodiments, the swellable material is configured with a related non - swellable material covering at least a portion of the swellable material, and in such embodiments, the related non - swellable material may contact the movable arms. I. Pharmaceutical Dosage Forms Configured for Other Cavities

[0169] The concept of the pharmaceutical dosage forms or medical devices of the present invention can be applied not only to oral administration but also to other parts of the human body, such as the large intestine, small intestine, rectum, cecum, colon, vagina, etc., and the pharmaceutical dosage forms or medical devices described in the present invention are also applicable. Those of ordinary skill in the art will readily understand that these other cavities may have anatomical features that guide the pharmaceutical dosage forms described herein. For example, the anatomical size of the rectum can guide the size of the pre - dosing pharmaceutical dosage form for such use, which may be different from the size of the oral pharmaceutical dosage form in certain embodiments. That being said, the mechanisms of retention in an individual taught herein still apply. III. Commercial Batches

[0170] In some aspects, provided herein are oral pharmaceutical dosage forms of commercial batches as described herein. In some embodiments, the commercial batch comprises at least any one of 100, 150, 200, 250, 500, 750, 1,000, 2,500, 5,000, 7,500, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000 or 100,000 oral pharmaceutical dosage forms as described herein. In some embodiments, each oral pharmaceutical dosage form of the commercial batch is produced using the same technique, such as involving three-dimensional (3D) printing, injection molding, ultrasonic welding, or any combination thereof, of one or more components of the oral pharmaceutical dosage form.

[0171] In some embodiments, for one or more of the following, the standard deviation of the commercial batch is about 0.1 or less, such as 0.05 or lower: the amount of drug in the oral pharmaceutical dosage form; the weight of the oral pharmaceutical dosage form; the size of the oral pharmaceutical dosage form (e.g., in the pre-administration state and / or the post-administration state); and the gastric retention time of the oral pharmaceutical dosage form. In some embodiments, the size of the oral pharmaceutical dosage form is the maximum cross-sectional dimension in the pre-administration state of the oral pharmaceutical dosage form. In some embodiments, the size of the oral pharmaceutical dosage form is a cross-sectional dimension perpendicular to the maximum cross-sectional dimension of the oral pharmaceutical dosage form in the pre-administration state. In some embodiments, the size of the oral pharmaceutical dosage form is the maximum cross-sectional dimension after swelling of the swellable material of the oral pharmaceutical dosage form (e.g., in the post-administration state in the stomach, where the swellable material has swollen to a substantially complete state). In some embodiments, the size of the oral pharmaceutical dosage form is a cross-sectional dimension perpendicular to the maximum cross-sectional dimension of the oral pharmaceutical dosage form after swelling of the swellable material (e.g., in the post-administration state in the stomach, where the swellable material has swollen to a substantially complete state). IV. Preparation Method

[0172] In some aspects, provided herein is a method for preparing the oral pharmaceutical dosage forms as described herein. In some embodiments, the manufacturing method comprises three-dimensional (3D) printing technology to form at least one component or a portion thereof of the pharmaceutical dosage form as described herein. In some embodiments, the manufacturing method comprises using 3D printing, injection molding, ultrasonic welding, or any combination thereof. In some embodiments, the components of the oral pharmaceutical dosage forms taught herein are produced separately and then assembled by machine and / or by hand.

[0173] As used herein, the terms "printing", "three-dimensional printing", "3D printing", "additive manufacturing", or their equivalents, refer to the process of producing three-dimensional objects layer by layer using a digital design, such as a delayed-release oral drug dosage form. The basic processes of three-dimensional printing are described in U.S. Patent Nos. 5,204,055; 5,260,009; 5,340,656; 5,387,380; 5,503,785; and 5,633,021. Other U.S. patents and patent applications related to three-dimensional printing include: U.S. Patent Nos. 5,490,962; 5,518,690; 5,869,170; 6,530,958; 6,280,771; 6,514,518; 6,471,992; 8,828,411; U.S. Patent Publication Nos. 2002 / 0015728; 2002 / 0106412; 2003 / 0143268; 2003 / 0198677; 2004 / 0005360. The contents of the above U.S. patents and patent applications are hereby incorporated by reference in their entirety into this document. In some embodiments, additive manufacturing techniques are used to produce the oral drug dosage forms or their components described herein. In some embodiments, layer-by-layer techniques are used to produce the oral drug dosage forms or their components described herein. For example, in some embodiments, the layer-by-layer technique includes printing one or more materials of the entire first layer of the oral drug dosage form or its components, and then continuing to print one or more materials of the entire second layer of the oral drug dosage form or its components. In some embodiments, the layer, such as the first layer or the second layer, is a cross-section of the oral drug dosage form or its components. Since 3D printing can handle a range of drug materials and locally control the composition and structure, 3D printing is well-suited for manufacturing drug dosage forms with complex geometries and compositions according to the present invention.

[0174] In some embodiments, when referring to the components of a pharmaceutical dosage form, such as a swellable material, a layer refers to the configuration of the components of an oral pharmaceutical dosage form and may include multiple printed layers of the same material. In some embodiments, the layer has a predetermined packing density, such as the packing density of three-dimensional printing. In some embodiments, the layer includes from about 5 printed layers to about 2500 printed layers between multiple printed layers, such as between about 10 printed layers and about 2500 printed layers, between about 25 printed layers and about 100 printed layers, between about 50 printed layers and about 200 printed layers, between about 100 printed layers and about 200 printed layers, between about 150 printed layers and about 250 printed layers, between about 200 printed layers and about 250 printed layers, between about 500 printed layers and about 1000 printed layers, or between about 2000 printed layers and about 2400 printed layers. In some embodiments, the thickness of the printed layer does not exceed about 5 mm, such as not exceeding about 4 mm, 3 mm, 2 mm, 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, 0.1 mm, 0.09 mm, 0.08 mm, 0.07 mm, 0.06 mm, 0.05 mm, 0.04 mm, 0.03 mm, 0.02 mm, or 0.01 mm. In some embodiments, the thickness of the printed layer is about 5 mm, 4 mm, 3 mm, 2 mm, 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, 0.1 mm, 0.09 mm, 0.08 mm, 0.07 mm, 0.06 mm, 0.05 mm, 0.04 mm, 0.03 mm, or 0.01 mm.

[0175] In terms of raw materials, equipment, and curing, different 3D printing methods have been developed for manufacturing. These 3D printing methods include binder deposition (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing., 2ed. Springer, New York, 2015; Katstra et al., Oral dosage forms fabricated by three dimensional printing, J Control Release, 66, 2000; Katstra et al., Fabrication of complex oral delivery forms by three dimensional printing, Dissertation in Materials Science and Engineering, Massachusetts Institute of Technology, 2001; Lipson et al., Fabricated: The New World of 3D printing, John Wiley & Sons, Inc., 2013; Jonathan, Karim 3D printing in pharmaceutics: a new tool for designing customized drug delivery systems, Int J Pharm, 499, 2016), material jetting (see Jonathan, Karim, 3D printing in pharmaceutics: a new tool for designing customized drug delivery systems, Int J Pharm, 499, 2016), extrusion (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing. 2ed. Springer, New York, 2015), and photopolymerization (see Melchels et al.,A review on stereolithography and its application in biomedical engineering.Biomaterials, 31, 2010).

[0176] In some embodiments, the oral drug dosage forms described herein are 3D printed using an extrusion method. In some embodiments, the 3D printing method includes using a twin-screw extrusion method. During extrusion, the material is extruded through a printing nozzle from a robot-driven print head. Different from binder deposition that requires a powder bed, the extrusion method can print on any substrate. A variety of materials can be extruded for three-dimensional printing, including the thermoplastics, pastes and colloidal suspensions, silicones, and other semi-solids disclosed herein. One extrusion printing method is melt extrusion deposition (MED), which uses the extruded material from the print head to print layers of material to form components of the oral drug dosage form or its components. Another common type of extrusion printing is fused deposition modeling, which uses solid polymer filaments for printing. In fused deposition modeling, a gear system drives the wire into a heated nozzle assembly for extrusion (see Gibson et al., Additive Manufacturing Technologies: 3D Printing, Rapid Prototyping, and Direct Digital Manufacturing, 2nd ed., Springer, New York, 2015).

[0177] In some embodiments, 3D printing is performed by melt extrusion deposition (MED). In some embodiments, the melt extrusion deposition technique includes preparing the material to be printed, such as preparing a powder in a hot melt extruder, and then feeding the material into the MED print head. Then, the MED print head prints the material in an additive manner (layer-by-layer deposition) to form the oral drug dosage form or its components. In some embodiments, each material or its components of the oral drug dosage form are printed from a different MED print head. In some embodiments, the MED print head prints the material according to instructions in one or more gcode files. For example, WO2019 / 137333, WO2018137686, and U.S. Patent No. 10,201,503 disclose exemplary MED techniques, each of which is incorporated herein by reference in its entirety.

[0178] In some embodiments, 3D printing is performed by fused deposition modeling (FDM). In some embodiments, three-dimensional printing is performed by fused extrusion deposition or hot melt extrusion in combination with 3D printing techniques such as FDM. In some embodiments, 3D printing is performed by non-wire FDM. In some embodiments, 3D printing is performed by inkjet printing. In some embodiments, 3D printing is performed by selective laser sintering (SLS). In some embodiments, 3D printing is performed by stereolithography (SLA or SL). In some embodiments, 3D printing is performed by PolyJet, multi-jet printing system (MJP), Perfactory, solid object ultraviolet laser printer, bioplotter, 3D bioprinting, rapid freeze prototyping, desktop system, selective deposition lamination (SDL), laminated object manufacturing (LOM), ultrasonic consolidation, color jet printing (CJP), EOSINT system, laser engineered net shaping (LENS), and aerosol jet system, electron beam melting (EBM), laser selective laser melting (SLM), Phenix PXTM series, micro sintering, digital part materialization (DPM), or VX system.

[0179] In some embodiments, the 3D printing methods described herein include continuous production methods. In some embodiments, the 3D printing methods described herein include batch production methods.

[0180] In some embodiments, the methods for producing pharmaceutical dosage forms described herein include 3D printing techniques, such as a combination of 3D printing with another method, e.g., a combination of injection molding and 3D printing. In some embodiments, the methods for production further include injection molding techniques. In some embodiments, the production methods further include ultrasonic welding methods. In some embodiments, the 3D printing techniques, injection molding techniques, and ultrasonic welding methods can be used alone or in any combination.

[0181] The method specifications for 3D printing pharmaceutical dosage forms disclosed herein can be generated in a variety of ways, including direct coding, derivation from solid CAD models, or other means specific to 3D printer computer interfaces and application software. These instructions may include information about the number and spatial location of droplets, as well as information about general 3D printing parameters, such as droplet spacing in each linear dimension (X, Y, Z) and the volume or mass of each droplet. For a given set of materials, these parameters can be adjusted to improve the quality of the created structure. The overall resolution of the created structure is a function of powder particle size, droplet size, printing parameters, and material properties.

[0182] In some embodiments, one or more components of the oral pharmaceutical dosage form are created separately, e.g., printed separately and then assembled to form the oral pharmaceutical dosage form. In some embodiments, all components of the oral pharmaceutical dosage form are created in a single process, e.g., printed in a single process without subsequent assembly.

[0183] The oral pharmaceutical dosage forms and their components described in this application can be printed on a commercial scale. For example, in some embodiments, the methods disclosed herein can be used to 3D print 1,000 to 100,000 units of oral pharmaceutical dosage forms per hour, including printing their components for subsequent assembly.

[0184] In some embodiments, the materials for printing the oral pharmaceutical dosage form or its components are printed by different print heads separately. The 3D printing methods described herein include printing the materials in any order to allow for the production of the oral pharmaceutical dosage form or its components.

[0185] In some embodiments, the method for 3D printing includes designing all or part of the oral pharmaceutical dosage form or its components on a computer system. In some embodiments, the method includes inputting the desired gastric retention, drug release profile, and / or parameters of the oral pharmaceutical dosage form and / or components into the computer system. In some embodiments, the method includes providing one or more parameters to be printed, e.g., layer surface area, thickness, drug mass fraction, erosion rate. In some embodiments, the method includes providing the desired drug release profile. In some embodiments, the method includes creating a virtual image of the item to be printed. In some embodiments, the method includes creating a computer model containing the predetermined parameters. In some embodiments, the method includes feeding the predetermined parameters into a 3D printer and printing the item according to these predetermined parameters. In some embodiments, the method includes creating a 3D drawing of the item to be printed based on the predetermined parameters, wherein the 3D drawing is created on a computer system. In some embodiments, the method includes converting the 3D drawing such as a slice into 3D printing code, e.g., G-code. In some embodiments, the method includes using the computer system to execute the 3D printing code, thereby performing the printing according to the methods described herein. V. Methods of Delivering a Drug to an Individual

[0186] In some aspects, a method of delivering an oral dosage form to an individual is provided such that the oral dosage form remains in the individual's stomach for an extended period of time. The method includes orally administering to the individual any of the oral dosage forms described herein. In some aspects, a method of delivering a drug to the stomach and / or upper gastrointestinal tract of an individual is provided, the method including orally administering to the individual any of the oral dosage forms described herein, wherein the oral dosage form includes a drug. In some embodiments, the drug is released from the oral dosage form into the stomach and / or upper gastrointestinal tract over an extended period of time (including sustained release profiles, delayed release profiles, pulsatile release profiles, or any combination thereof). In some embodiments, the oral dosage form is configured to remain in the individual's stomach for an extended period of time (e.g., at least about 8 hours to about 3 months). In some embodiments, the drug in the oral dosage form can be released from the oral dosage form at a predetermined time after the oral dosage form is administered to the individual. For example, in some embodiments, the drug or at least a portion thereof is released in the individual's stomach because, or subsequent to, the oral dosage form reaching a post-administration state designed for gastric retention. In some embodiments, the drug or at least a portion thereof is released in the individual's stomach for at least about 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, 32 hours, 34 hours, or 36 hours after the drug dosage form is administered to the individual.

[0187] Those skilled in the art will recognize that several embodiments can be implemented within the scope and spirit of the disclosure of this application. The following examples further illustrate the disclosure, and these examples should not be construed as limiting the scope or spirit of the disclosure to the specific procedures described therein. Examples Example 1

[0188] This example demonstrates the design and testing of an oral dosage form for gastric retention described herein.

[0189] Based on Figures 5A - 5F Two demonstration models of the shown design configuration were 3D printed using a swellable material (LHB1:NaCl = 9:1). For both models, the body and the movable arm were printed using a photosensitive resin. After printing, the two demonstration models were immersed in water such that the swellable material could swell and force the movable arm to rotate and extend towards or away from the body of the oral dosage form. At certain time points, the angle between the two movable arms was measured to evaluate the degree of dimensional expansion that the dosage form could achieve upon swelling. The material formulations of the swellable components tested and their corresponding results are shown in Table 1 and Figure 16 as shown. Table 1. Details of the test models. Example 2

[0190] This example demonstrates the design and testing of the pharmaceutical dosage forms for gastric retention described herein.

[0191] Based on Figures 7A - 7I Two demonstration models based on the shown design configuration were 3D printed. The two demonstration models were printed with fluid inlets of different designs on the body, allowing fluid to enter the swellable material chamber. The body of one model had fluid inlets only on the side walls of the swellable chamber, while the body of the other model had fluid inlets on the top, bottom, and side walls of the swellable material chamber. The directional channels in the body part were covered by two lids on both sides to replace the movable arms. All the liquid inlets were Φ1mm. The cross-section of the third channel connecting the swellable chamber and the first directional channel in the body was 3.5mm x 4mm. The swellable material used for this test was PAANa (30 - 60 mesh). The rest of the body and the two lids were printed with photosensitive resin.

[0192] After printing, the models were immersed in a fluid with a pH of 1.0, such that the sides of the swellable chamber and the fluid inlets of the body were immersed in water, while one side of the first directional channel with the lid remained above the fluid. The extent to which the swellable material extended beyond the swellable material chamber and filled the first directional channel over a certain period of time was tested and recorded.

[0193] The designs of the fluid inlets in the two demonstration models are shown in Table 2. Table 2. Details of the model fluid inlets.

[0194] The swellable materials of Model 1 and Model 2 completely filled the first directional channel within 2 minutes ( Figure 17 ). Example 3

[0195] This example demonstrates the design and testing of the oral pharmaceutical dosage forms described herein, which are configured for gastric retention.

[0196] Based on Figures 8A - 8I Ten replicated demonstration models based on the shown design configuration were 3D printed. The preparation methods, specific functions, and component materials of the oral pharmaceutical dosage forms are summarized in Table 3. Table 3. Details of specific components of the oral pharmaceutical dosage form.

[0197] For each demonstration model, the bottom frame and the lid are printed with photosensitive resin. The swellable material chamber is printed with EC:ATBC:BaSO4 = 65:15:20. The erodible restrictor is printed with VA64:TEC = 9:1. The swellable material is a superabsorbent polymer (30 - 60 mesh). The movable arm is printed with EC:ATBC:BaSO4 = 60:20:20. Five of the models are placed with the bottom down and the arm face up (extended upward), and the remaining five models are placed in water with the bottom up and the arm face down (extended downward). Under different conditions, the degree to which the arm extends during swelling is as Figure 18 shown. As Figure 18 shown, the demonstration model of the oral drug dosage form can form a state of up to 30 mm x 30 mm within 30 minutes after administration. Example 4

[0198] This example demonstrates the design and testing of the oral drug dosage forms described herein, which are configured for gastric retention.

[0199] Based on Figures 9A - 9I the design configuration shown, 10 replicated demonstration models were fabricated. The preparation method, specific functions, and component materials of the oral drug dosage form are summarized in Table 4. Table 4. Details of specific components of the oral drug dosage form.

[0200] For each demonstration model, the bottom frame, the lid, and the movable arm are printed with photosensitive resin. The swellable material chamber is printed with EC:ATBC:BaSO4 = 65:15:20. The erodible restrictor is printed with VA64:TEC = 9:1. The swellable component is printed with a superabsorbent polymer (30 - 60 mesh). These ten demonstration models are immersed in water, and the arm is measured over time. The degree to which the arm unfolds during swelling is shown in Table 5. Table 5. Arm extension measurements for each demonstration model.

[0201] The size of the oral drug dosage form when swollen was also examined in vivo. To enable in vivo imaging, BaSO 4 was included in the formulation of the swellable material chamber. In addition, a strip with a tracer was attached to the surface of the movable arm to visualize the position of the arm.

[0202] This study used a male beagle dog. The dog was fasted for 14 hours while drinking water before the administration of the oral drug dosage form. Dog food was provided 4 hours after the administration of the oral drug dosage form, and water was provided throughout the experiment. The drug dosage form was swallowed whole with 20 mL of water without breaking, chewing, or grinding. To evaluate the residence time and status of the oral drug dosage form, radiographs of the drug dosage form were collected before dosing and at 10 min, 30 min, 1 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 10 h, 14 h, 24 h, and 26 h after dosing. For each time point, anterior and lateral view images were taken. The collected X-ray images, the position of the drug dosage form, and the extent to which the movable arm extended at each collection time point are provided in Figure 19A and 19B As shown in Figure 19A and 19B the oral drug dosage form remained in the stomach for a long time with the movable arm in the extended position, and the oral drug dosage form was able to remain in the stomach for at least about 14 hours. Example 5

[0203] This example demonstrates the design and testing of the oral drug dosage forms described herein, which are configured for gastric retention.

[0204] Based on the design configuration shown in Figures 14A - 14B a demonstration model was fabricated.

[0205] For the demonstration model, the bottom frame, lid, and movable arm were injection molded using PLA and ABS. The swelling component was tabletted with PEO700W:CCNa:BaSO 4 = 56:24:20. The erodible restraint was printed with VA64:TEC = 85:15.

[0206] The size of the oral drug dosage form when swollen was examined in vivo. To enable in vivo imaging, BaSO 4 was included in the formulation of the swellable material chamber. In addition, a strip with a developer was attached to the surface of the movable arm to visualize the position of the arm.

[0208] A male beagle dog was used in this study. The dog was fasted for 14 hours while drinking water before the administration of the oral drug dosage form. Dog food was provided 4 hours after the administration of the oral drug dosage form, and water was provided throughout the experiment. The drug dosage form was swallowed whole with 20 mL of water without breaking, chewing, or grinding. To evaluate the residence time and status of the oral drug dosage form, X-ray images of the drug dosage form were collected before dosing and at 30 h, 1.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 23 h, 24 h, 30 h, 36 h, 48 h, and 52 h after dosing. For each time point, anterior and lateral view images were taken. The collected X-ray images, the position of the drug dosage form, and the extent of the movable arm extension at each collection time point are provided in Figure 20A and 20B . As shown in Figure 20A and 20B , the oral drug dosage form remained in the stomach for a long time with the movable arm in the extended position, and the oral drug dosage form was able to remain in the stomach for at least about 36 hours. Example 6

[0209] The drug dosage form model was fixed in a clamp, and then the bottom was immersed in 5 mL of purified water medium, and the unfolding of the unfolding arm was observed, as shown in Figure 22A . It was found that the unfolded arm unfolded 120° within 5 minutes, as shown in Figure 23B . The above experiments showed that the retention of the drug dosage form in vivo could be manifested in less liquid, with potential applications in colon retention or vaginal retention. Example 7

[0210] This example demonstrated the design and testing of the oral drug dosage forms described herein, which were configured for gastric retention.

[0211] Based on the design configuration shown in Figures 22A - 22B , a demonstration model was made.

[0212] For the demonstration model, the bottom frame, lid, and movable arm were all made of HPMC, and the swellable component was a PEO tablet.

[0213] This study aimed to evaluate the in vivo safety after 7 consecutive days of oral administration of the placebo candidate formulation by gastroscopy, fecal occult blood (OB) test, and collection of residues from feces.

[0214] The placebo candidate formulation was orally administered once a day for 7 consecutive days by 3 beagle dogs under feeding conditions. Gastroscopy was performed on day 0 (before dosing) and day 8 (after the last dosing), and OB tests were performed daily to evaluate the in vivo safety when the beagle dogs were orally administered the placebo candidate formulation.

[0215] Gastroscopic examination of 3 beagle dogs that orally received the placebo candidate for 7 consecutive days showed that no changes were observed on day 8 compared with day 0, indicating that no directly observable damage occurred during the administration. Gastroscopic examination (day 0 and day 8) showed Figure 24 .

[0216] The results of occult blood tests on feces collected during 7 consecutive days of administration were all negative, indicating that the placebo candidate preparation did not cause any damage to the gastrointestinal tract of beagle dogs during the gastrointestinal transit. The results of the fecal occult blood test were as Figure 25 shown.

[0217] The residues of the placebo candidate preparation were collected, and all residues were softened. Pictures of the residues collected from the feces of beagle dogs are as Figure 26 shown.

[0218] The beagle dogs ate and moved normally after orally receiving the candidate preparation for 7 consecutive days. No gastrointestinal damage was observed in the beagle dogs during the administration period.

Claims

1. An oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; a movable arm configured such that at least a portion of the movable arm can be extended into or rotated around the body of the oral pharmaceutical dosage form by a force provided by the swellable material; and the body comprising: a swellable material chamber configured to contain at least a portion of the swellable material; wherein the swellable material chamber operably includes one or more fluid inlets; an orienting channel and an orifice operably connected to the swellable material chamber, wherein the movable arm includes a contact assembly configured to contact the swellable material or a feature associated with the swellable material near the orienting channel and the orifice; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

2. The oral pharmaceutical dosage form according to claim 1, wherein, the features associated with the swellable material include a plunger or a piston.

3. The oral pharmaceutical dosage form according to claim 1, wherein, the movable arm or the body includes a pivot, and the movable arm is connected to the body by the pivot.

4. The oral pharmaceutical dosage form according to claim 1, wherein, the swellable material chamber includes a lid and a base, and the pivot of the movable arm is connected to the lid.

5. The oral pharmaceutical dosage form according to any one of claims 1 - 4, wherein, the post - administration state of the oral pharmaceutical dosage form occurs within 2 hours or less after the oral pharmaceutical dosage form is administered to an individual.

6. The oral pharmaceutical dosage form according to any one of claims 1 - 4, wherein, the gastric retention time of the oral pharmaceutical dosage form is about 6 hours to about 3 months.

7. The oral pharmaceutical dosage form according to any one of claims 1 - 4, wherein, the swellable material swells to at least about 1.2 times its volume after exposure to gastrointestinal fluid.

8. The oral pharmaceutical dosage form according to any one of claims 1 - 5, wherein, the swellable material has a volume expansion rate of at least about 1.2 times within 30 minutes.

9. The oral pharmaceutical dosage form according to any one of claims 1 - 5, wherein, when the swellable material swells, it at least partially conforms to the shape of the orienting channel and the orifice or a part thereof.

10. The oral pharmaceutical dosage form according to any one of claims 1 - 5, wherein, when the swellable material swells, it adopts a predetermined shape and / or size.

11. The oral pharmaceutical dosage form according to any one of claims 1 - 5, wherein, the amount of the swellable material in the swellable material chamber is at least about 5 mg.

12. The oral pharmaceutical dosage form according to any one of claims 1 - 5, wherein, The swellable material includes sodium alginate (SA), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methylcellulose (HPMC), polyethylene oxide (PEO), polyvinyl alcohol (PVA), microcrystalline cellulose (MCC), croscarmellose sodium (CCNa), sodium carboxymethyl cellulose (CMC-Na), polyvinylpolypyrrolidone (PVPP), sodium carboxymethyl starch (CMS-Na), polyethylene glycol (PEG) or a mixture thereof.

13. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the swellable material includes a gas-generating substance.

14. The oral pharmaceutical dosage form according to claim 13, characterized in that the swellable material further includes a salt or a mixture of salts, wherein the salt is selected from the group consisting of sodium salts, magnesium salts and potassium salts.

15. The pharmaceutical dosage form according to any one of claims 1-5, characterized in that The swellable material has a swell volume of from about 10 mm 3 to about 50 mm 3 ​ 16. The pharmaceutical dosage form according to claim 2, characterized in that The plunger or piston push arm rotates around the main body into an unfolded form.

17. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the main body is configured to include two or more components to form the main body.

18. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the main body contains two or more materials.

19. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the main body of the oral pharmaceutical dosage form is an integral structure.

20. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the maximum cross-sectional dimension of the oral pharmaceutical dosage form in the pre-administration state is 24 mm or less.

21. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that at least two perpendicular dimensions of the oral pharmaceutical dosage form in the post-administration state are 20 mm or more.

22. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the swellable material chamber is configured to substantially contain the swellable material in the pre-administration state.

23. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the contact assembly of the swellable material chamber and the movable arm substantially surrounds the swellable material.

24. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the guiding channel is configured to guide the movement of the movable arm through the swellable material.

25. The oral pharmaceutical dosage form according to any one of claims 1-5, characterized in that the guiding channel includes a curved channel, a straight channel, a circular channel, an elliptical channel, a capsule-shaped channel, a square or rectangular channel.

26. The pharmaceutical dosage form according to any one of claims 1-4, characterized in that the pharmaceutical dosage form can be taken orally or is located in the stomach, small intestine, large intestine, rectum, colon, vagina.

27. The oral pharmaceutical dosage form according to claim 4, characterized in that the main body or matrix is a semi-permeable membrane.

28. The oral pharmaceutical dosage form according to claim 27, wherein, at least one of the one or more fluid inlets is a semi-permeable material that fills the pores formed by the body.

29. The oral pharmaceutical dosage form according to any one of claims 1-5, wherein, at least one of the one or more fluid inlets is a pore.

30. The oral pharmaceutical dosage form according to any one of claims 1-5, wherein, the body further forms a stop configured to engage with the movable arm in the extended position.

31. The oral pharmaceutical dosage form according to claim 30, wherein, the stop includes a locking assembly configured to hold the movable arm in one or more extended positions.

32. The oral pharmaceutical dosage form according to any one of claims 1-5, wherein, the wall thickness of the body is at least about 0.4 mm.

33. The oral pharmaceutical dosage form according to any one of claims 1-5, wherein, the at least two movable arms have different movement mechanisms or the same movement mechanism.

34. The oral pharmaceutical dosage form according to any one of claims 1-5, further comprising a second swellable material at least partially contained in a second swellable material chamber formed by the body, wherein at least one movable arm is configured such that at least a portion of the movable arm can be extended out of or further away from the body of the oral pharmaceutical dosage form or rotated around the body by the force provided by the second swellable material.

35. The oral pharmaceutical dosage form according to any one of claims 1-5, wherein, the thickness of the arm is at least about 1 mm.

36. The oral pharmaceutical dosage form according to any one of claims 1-5, further comprising an erodible restraint configured to inhibit the extension of the movable arm.

37. The oral pharmaceutical dosage form according to claim 36, wherein, the erodible restraint is eroded within about 30 minutes after administration to an individual.

38. The oral pharmaceutical dosage form according to any one of claims 1-5, wherein, the drug is located in one or more of the following: the movable arm and / or the body.

39. The oral pharmaceutical dosage form according to claim 38, wherein, the drug is selected from the following group: riociguat, aceclofenac, bicalutamide, carbamazepine, carvedilol, clotrimazole, cinnarizine, danazol, dapsone, estradiol, ezetimibe, glibenclamide, fenofibrate, griseofulvin, ibuprofen, itraconazole, ketoconazole, mefenamic acid, naproxen, nevirapine, nitrendipine, nitrofurantoin, nomegestrol acetate, phenytoin sodium, piroxicam, praziquantel, rifampicin, sulfamethoxazole, trimethoprim, verapamil hydrochloride.

40. An oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a swellable material; movable arms configured such that at least a portion of the movable arms can be extended out of the body of the oral pharmaceutical dosage form or further away by the force provided by the swellable material; the body includes: a swellable material chamber configured to contain at least a portion of the swellable material; A directional channel operably connected to a swellable material chamber, wherein the movable arm includes a contact assembly configured to contact the swellable material in proximity to the directional channel, wherein the swellable material chamber and the contact assembly of the movable arm substantially surround the swellable material, and wherein the movable arm or a portion thereof is configured to slide within the directional channel such that the movable arm extends out of or further away from the body of the oral dosage form along an axis based on the directional channel; One or more fluid inlets operably connected to the swellable material chamber; A stop engaging the movable arm in an extended position; and A drug, wherein the oral dosage form is configured to have a pre - dosing state in a compact form and a post - dosing state in an expanded form providing gastric retention, and wherein the expanded form of the post - dosing state of the oral dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

41. The oral dosage form according to claim 40, wherein, the stop includes a locking assembly configured to hold the movable arm in one or more extended positions.

42. The oral dosage form according to claim 41, wherein, the locking assembly is configured to hold the movable arm in a single position.

43. The oral dosage form according to claim 42, wherein, the locking assembly is configured to hold the movable arm in a plurality of advanced positions.

44. An oral dosage form for gastric retention, the oral dosage form comprising: A swellable material; A first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended out of or further away from the body of the oral dosage form by a force provided by the swellable material, and wherein the first movable arm and the second movable arm extend in substantially opposite directions along an axis based on the directional channel; The body includes: A swellable material chamber configured to contain at least a portion of the swellable material; A first directional channel and a second directional channel operably connected to the swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the swellable material in proximity to the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the swellable material in proximity to the second directional channel, wherein the swellable material chamber, the first contact assembly of the first movable arm, and the second contact assembly of the second movable arm substantially surround the swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel, such that the first movable arm extends out of or further away from the body of the oral dosage form along an axis, and wherein the second movable arm or a portion thereof is configured to slide within the second directional channel, such that the second movable arm extends out of or further away from the body of the oral dosage form along the axis; One or more fluid inlets operably connected to the swellable material chamber; A first stop configured to engage the first movable arm in an extended position; A second stop configured to engage with the second movable arm in an extended position; and a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of a swellable material in the presence of gastrointestinal fluid.

45. An oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a first swellable material; a first movable arm, wherein the first movable arm is configured such that at least a portion of the movable arm can be extended beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the first swellable material, and wherein the first movable arm is configured to rotate about a first axis; a second swellable material; a second movable arm, wherein the second movable arm is configured such that at least a portion of the movable arm can be extended beyond or further from the body of the oral pharmaceutical dosage form by a force provided by the second swellable material, and wherein the second movable arm is configured to rotate about a second axis; the body comprising: a first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel operatively connected to the first swellable material chamber, wherein the first directional channel comprises a curved - shaped channel, wherein the first movable arm comprises a first contact assembly configured to contact the first swellable material near the first directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm substantially surround the first swellable material, and wherein the first movable arm or a portion thereof is configured to rotate about the first axis by the first contact assembly sliding on the first directional channel such that the first movable arm extends out or further from the body of the oral pharmaceutical dosage form, one or more fluid inlets operatively connected to the first swellable material chamber; a second swellable material chamber configured to contain at least a portion of the second swellable material; a second directional channel operatively connected to the second swellable material chamber, wherein the second directional channel comprises a curved - shaped channel, wherein the second movable arm comprises a second contact assembly configured to contact the second swellable material in the vicinity of the second directional channel, wherein the second swellable material chamber and the second contact assembly of the second movable arm substantially surround the second swellable material, and wherein the second movable arm or a portion thereof is configured to rotate about the second axis by the second contact assembly sliding on the second directional channel such that the second movable arm extends to or further extends out of the body of the oral pharmaceutical dosage form, one or more fluid inlets operatively connected to the second swellable material chamber; a drug, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of a swellable material in the presence of gastrointestinal fluid.

46. An oral pharmaceutical dosage form for gastric retention, the oral pharmaceutical dosage form comprising: a first swellable material; A first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended beyond or further from the body of the oral dosage form by the force provided by the first swellable material, and wherein the first movable arm and the second movable arm extend in substantially opposite directions along an axis based on the directional channels; A second swellable material; A third movable arm, wherein the third movable arm is configured such that at least a portion of the third movable arm can be extended beyond or further from the body of the oral dosage form by the force provided by the second swellable material, and wherein the third movable arm is configured to rotate about a first axis; A third swellable material; A fourth movable arm, wherein the fourth movable arm is configured such that at least a portion of the fourth movable arm can be extended beyond or further from the body of the oral dosage form by the force provided by the third swellable material, and wherein the fourth movable arm is configured to rotate about a second axis; The body includes: A first swellable material chamber configured to contain at least a portion of the first swellable material; a first directional channel and a second directional channel are operably connected to the first swellable material chamber, wherein the first movable arm includes a first contact assembly configured to contact the first swellable material near the first directional channel, wherein the second movable arm includes a second contact assembly configured to contact the first swellable material near the second directional channel, wherein the first swellable material chamber and the first contact assembly of the first movable arm and the second contact assembly of the second movable arm substantially surround the first swellable material, and wherein the first movable arm or a portion thereof is configured to slide within the first directional channel, such that the first movable arm extends along the axis out of or further from the body of the oral dosage form, and wherein the second movable arm or a portion thereof is configured to slide within the second directional channel, such that the second movable arm extends along the axis out of or further from the body of the oral dosage form; one or more fluid inlets are operably connected to the first swellable material chamber; A first stop configured to engage the first movable arm in the extended position; A second stop configured to engage the second movable arm in the extended position; A second swellable material chamber configured to contain at least a portion of the second swellable material; A third directional channel is operably connected to the second swellable material chamber, wherein the third directional channel includes a curved channel, wherein the third movable arm includes a contact assembly configured to contact the second swellable material near the third directional channel, wherein the second swellable material chamber and the contact assembly of the third movable arm substantially surround the second swellable material, and wherein the third movable arm or a portion thereof is configured to rotate about the first axis by sliding the contact assembly along the third directional channel such that the third movable arm extends out of or further from the body of the oral dosage form, One or more fluid inlets are operably connected to the third swellable material chamber; A third swellable material chamber configured to contain at least a portion of the third swellable material; A fourth guiding channel operably connected to the third swellable material chamber, wherein the fourth guiding channel includes a curved channel, wherein the fourth movable arm includes a contact assembly configured to contact the third swellable material in proximity to the fourth guiding channel, wherein the third swellable material chamber and the contact assembly of the fourth movable arm substantially surround the third swellable material, and wherein the fourth movable arm or a portion thereof is configured to rotate about a second axis by sliding the contact assembly along the fourth guiding channel such that the fourth movable arm extends out of or further away from the body of the oral dosage form, One or more fluid inlets operably connected to the third swellable material chamber; and A drug, wherein the oral dosage form is configured to have a pre - administration state in a compact form and a post - administration state in a deployed form providing gastric retention, and wherein the deployed form of the post - administration state of the oral dosage form is at least partially due to the swelling of the first swellable material, the second swellable material, and the third swellable material in the presence of gastrointestinal fluid.

47. An oral dosage form for gastric retention, the oral dosage form comprising: A swellable material; A first movable arm and a second movable arm, wherein the first movable arm and the second movable arm are configured such that at least a portion of each movable arm can be extended out of or further away from the body of the oral dosage form by a force provided by the swellable material, and wherein the first movable arm and the second movable arm are configured to rotate in opposite directions about a shared axis ; The body includes: A swellable material chamber configured to contain at least a portion of the swellable material; A first guiding channel and a second guiding channel operably connected to the swellable material chamber, wherein the first guiding channel and the second guiding channel are in a curved shape and are configured around the shared axis, wherein the first movable arm includes a first contact assembly configured to contact the swellable material in proximity to the first guiding channel, wherein the first contact assembly is in a rudder shape and is configured to travel in the first guiding channel such that the first movable arm rotates relative to the shared axis out of or further away from the body of the oral dosage form, wherein the second movable arm includes a second contact assembly configured to contact the swellable material in proximity to the second guiding channel, wherein the second contact assembly is in a rudder shape and is configured to travel in the second guiding channel such that the second movable arm rotates relative to the shared axis out of or further away from the body of the oral dosage form, One or more fluid inlets operably connected to the swellable material chamber; A stop configured to engage with the first movable arm and the second movable arm in an extended position; A drug, wherein the oral dosage form is configured to have a pre - administration state in a compact form and a post - administration state in a deployed form providing gastric retention, and wherein the deployed form of the post - administration state of the oral dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

48. An oral dosage form for gastric retention, the oral dosage form comprising: A swellable material, wherein the swellable material is at least partially encapsulated by a semipermeable membrane; A first movable arm, a second movable arm, wherein the first movable arm and the second movable arm are configured such that each arm rotates in a direction perpendicular to the positioning plane along an independent axis by a force provided by the swellable material; and The body includes: A first connection point of the first arm, a second connection point of the second arm, wherein each connection point is configured to provide an independent axis for the rotation of the first arm and the second arm, wherein each movable arm includes a contact assembly configured to contact the swellable material or the semipermeable material, and A first stop and a second stop are respectively configured to engage with the first movable arm and the second movable arm in the extended position, wherein the oral pharmaceutical dosage form is configured to have a pre - administration state in a compact form and a post - administration state in an expanded form that provides gastric retention, and wherein the expanded form of the post - administration state of the oral pharmaceutical dosage form is at least partially due to the swelling of the swellable material in the presence of gastrointestinal fluid.

49. The oral pharmaceutical dosage form according to claim 48, wherein, the swellable material is positioned on the body such that the swelling of the swellable material drives the first movable arm and the second movable arm to the extended position.

Citation Information

Patent Citations

  • Precision pharmaceutical 3D printing device

    US10201503B1

  • Dosage forms with desired release profiles and methods of designing and making thereof

    US10350822B1

  • Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form

    US20020015728A1

  • Method and materials for controlling migration of binder liquid in a powder

    US20020106412A1

  • System and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form

    US20030143268A1